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Introduction 
 
The third most common malignancy in the Netherlands is colorectal cancer. Rectal cancer 
affects every year around 2000 new patients. The highest incidence is found at an age 
above 70 years, and in men (sex ratio: 1.48). 
 
In Europe, the treatment of preference for locally advanced rectal cancer is surgery and 
preoperative radiotherapy. The addition of concurrent chemotherapy is currently 
investigated. However, these combined modality treatments induce side effects. 
Diarrhea is the major side effect of (neo-)adjuvant radiation therapy for rectal cancer [3, 
15]. An overview of acute and late severe bowel toxicity is given in tables 1.1-1.3.  
 
The relationship between the volume of small bowel irradiated and the development of 
diarrhea is well recognised [10, 13, 21]. In the seventies, large parallel opposed fields 
(APPA) were used [11]. They produced hotspots in areas which usually included large 
and small bowel and played a causative role in the toxicity profile of these patients. 
Exclusion of the small bowel from the pelvis in order to improve the tolerance to therapy 
has been the subject of a considerable number of research efforts.  First, the use of a three- 
or four-field beam arrangement with an abdominal wall compression device (belly board) 
and bladder distension was investigated [9, 17, 26]. An APPA-field set up with a patient 
in supine position resulted in an irradiation of  620 cm3 bowel. In contrast, a 4-field 
technique with a patient in prone position reduced the irradiated bowel volume to 145 cm3 
[10].  
 
The implementation of image guided conformal radiotherapy is a another way to reduce 
the amount of (small) bowel in the irradiation volume. Conformal radiotherapy using 
three-dimensional (3-D) treatment planning allows for more precise delivery of the 
irradiation and, therefore, better sparing of the surrounding critical normal tissues can be 
assumed. It also allows for higher doses compared to conventional radiotherapy. This 
technique has been widely used in prostate cancer. The contouring of the clinical target 
volume and the organs at risk (mainly rectum) combined with a dedicated 3-D treatment 
planning did result in dose escalation studies without increasing severe late complications 
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[29]. Chapter 2 reports low acute toxicity after dedicated 3-D conformal treatment 
planning in prostate cancer.  
 
Despite the good results of 3-dimensional conformal treatment planning in prostate 
cancer, this technique has not routinely been used for rectal cancer because of the lack of 
accurate data regarding the motion of the organs at risk and the clinical target volume 
(CTV). Chapter 3 describes the position and motion of the small bowel inside the pelvis in 
pre- and postoperative patients with rectal cancer and tries to explain why less bowel 
toxicity is seen in preoperative patients. The shape and motion of the clinical target 
volume for rectal cancer is presented in Chapter 4. This information is mandatory to treat 
a patient with 3-D conformal radiotherapy. However, due to the complex shape of the 
CTV, the gain of 3-D conformal radiotherapy was in fact little and therefore, the intensity 
modulated radiotherapy was introduced.  
With intensity modulated radiotherapy, we are able to create a more homogeneous dose 
inside the CTV and to reduce the dose to the surrounding critical organs. Chapter 5 
presents the reduction of small bowel exposure with intensity modulated radiotherapy 
planning compared to conventional treatment planning. 
 
Finally, another conformal radiotherapy technique is intraoperative brachytherapy 
(IOBT). This technique was developed to treat fixed or tethered rectal cancer that often 
invades the adjacent organs or pelvic wall. It involves the delivery of a single large 
radiation dose to residual tumour or to the tumour bed of a resected tumour at the time of 
surgery, while adjacent organs at risk like bowel can either be shielded or moved outside 
the treatment field. The intraoperative brachytherapy uses a remotely controlled high-
dose-rate (HDR) afterloader. The afterloader contains a small Iridium-192 point source 
mounted at the end of a steel wire. This source is transported under computer control into 
hollow afterloading catheters (stepping source technique). For IOBT, these catheters are 
embedded in a custom made silicon template. After tumour resection, an appropriately 
sized and shaped silicon template is placed on the residual tumour or on the tumour bed 
and secured into place. The dose is usually prescribed at 1 cm depth and according to the 
protocol, a dose of 10 Gy is to be delivered in these cases. The treatment time is either 
determined through individual planning after localisation of the IOBT geometry or using 
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preplanned atlases [12, 18]. The technique of intraoperative high-dose-rate brachytherapy 
is illustrated in Chapter 6 and chapter 7 presents the results of the first analysis of 39 
patients. 
 
Chapter 8 summarises the results and general conclusions of this thesis. 
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Table 1.1. Overview of acute severe bowel toxicity in randomised preoperative 
chemoradiotherapy trials 
author number of  treatment  total dose 
 patients RT + SU CT+RT+SU SU+RT+CT (Gy) 
Boulis-Wasif [4] 245 33 33 x 2.3 Gy x 15 
Hyams [15] 116 x 39 23 45 / 50.4 
Sauer [25] 805 x 13 12 50.4 
Bosset [3] 798 17 34 x 45 Gy 
Mean  25 30 23  
SU: surgery; RT: radiotherapy; CT: chemotherapy 
 
Table 1.2. Overview of acute severe bowel toxicity in preoperative chemoradiotherapy 
trials 
author number of percentage total type of 
 patients of toxicity dose (Gy) chemotherapy 
Mehta [19] 32 28 45 / 50.4 5-FU + CPT-11 
Kim [16] 45 4 45 / 50.4 Capecitabine 
Rodel [24] 26 54 50.4 Capecitabine & oxaliplatin 
Videtic [28] 29 3.4 48.5 / 60 5-FU 
De La Torre [6] 35 22 45 / 60 - 65 UFT 
Minsky [20] 20 17 46.8 / 50.4 5FU 
Mohiuddin [22] 33 15 45 / 60 5FU 
Dunst [7] 36 3 50.4 Capecitabine 
Reerink [23] 43 11 50 / 60 5FU + LV 
Mean  21   
 
 
Table 1.3: overview of late severe bowel toxicity in pre- and postoperative randomised 
(chemo)radiotherapy trials 
study number of 
patients 
Su 
alone
RT+ 
SU 
SU+ 
RT 
technique upper field 
border 
dose 
(Gy) 
Swedish rectal 
cancer [5] 
1168 10 30 x 3- or 4-field L5 25 
Uppsala [8] 471 6 5 11 3-Field mid L4 25 
Stockholm I [14] 572 7 11 x APPA L2 25 
Stockholm II [14] 455 8 9 x 4-field mid L4 25 
MRC III [1] 469 17 x 20 APPA 18x15 cm 40 
France [2] 172 0 20 x 4-field L4-L5 46 
Rotterdam [27] 172 x x 2 3- or 4-field L5-S1 50 
SU: surgery; RT: radiotherapy 
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Dose–volume relationship for acute side effects during high dose
conformal radiotherapy for prostate cancer
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Abstract
Purpose: To determine acute and late complications for bladder and rectum and to determine dose–volume correlations.
Methods and materials: Sixty-four patients received deﬁnitive treatment for prostate cancer between January 1995 and December 1998
using conformal three-dimensional radiotherapy. Doses ranged from 72 to 80 Gy. The acute and late side effects were gathered retro-
spectively, and graded according to Radiotherapy and Oncology Group criteria (RTOG). The patients were divided into two groups:#72 Gy
(Group A) and $76 Gy (Group B) and had a mean follow-up of 32 and 22 months, respectively.
Results: No grades 3–4 acute, urinary or rectal toxicity was reported. Acute grade 2 rectal complications were seen in 10 and 18% of the
patients in Groups A and B, respectively. They were observed at a mean dose of 38 Gy. Acute grade 2 urinary symptoms were 33 and 47% for
Groups A and B, respectively. They were seen at a mean dose of 43 Gy. Acute rectal symptoms were dose–volume related. Patients without
diarrhea had a mean rectal volume receiving a dose of 70 Gy or more of 8.5 cm3. However, patients with RTOG 2 diarrhea had a volume of
16.5 cm3 ðP ¼ 0:042Þ. No dose–volume relationship for acute bladder symptoms or late complications were seen. Grades 1–2 late rectal and
bladder complications were seen in 11 and 8% of the patients, respectively. None required hospital admission or transfusion.
Conclusion: Radiotherapy to the prostate can be given at 80 Gy. No grades 3–4 acute, urinary or rectal toxicity was reported. Acute rectal
symptoms are dose–volume related. q 2002 Elsevier Science Ireland Ltd. All rights reserved.
Keywords: Complications; Radiotherapy; Prostate cancer; Dose–volume relationship
1. Introduction
The dose of radiation that can be given is usually limited
by the need to restrict the number and severity of side
effects. Conformal radiotherapy using three-dimensional
(3D) treatment planning allows for more precise delivery
of treatment, more sparing of the surrounding normal tissues
and may allow higher doses compared to conventional
radiotherapy [21]. We initiated a conformal therapy prostate
cancer protocol in 1995, and have carefully escalated dose.
Current treatment doses range from 72 Gy and beyond
80 Gy, with excellent outcome and without major compli-
cations [5,7,14,16,27]. Several articles report that the treat-
ment with conformal radiotherapy produces fewer side
effects than conventional radiotherapy or surgery
[12,21,26]. Late side effects are ‘dose-limiting’, since they
are generally permanent and may be progressive in severity.
They have been studied more often [1,2,6,18,19,23,24] and
gastro-intestinal (GI) and genito-urinary (GU) side effects
are seen mostly during the ﬁrst 24 months of follow-up. Late
GU side effects occur at a mean time of 22 months, while
late rectal bleeding is seen at a mean time of 14 months [18]
or a median time of 17 or 18 months [6,23]. With doses up to
66 Gy, acute grades 1 and 2 rectal complications occur in 63
and 19% of the patients, respectively [9]. When higher
doses are used, the acute side effects are not well known.
We initiated a conformal therapy program at MUSC in the
beginning of 1995 and have escalated doses slowly from 72
to 80 Gy. From this group, we analyzed the incidence of
acute side effects, the dose at what they occur, and the
associated volumes. Because we have a short follow-up
for late complications, we report the preliminary late
complications.
2. Methods and materials
We initiated a retrospective study of all prostate cancer
patients treated with conformal therapy, with follow-up
* Corresponding author. Department of Radiation Oncology, Erasmus
MC-Daniel Den Hoed, Postbus 5201, 3008 AE Rotterdam, Netherlands.
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greater than 6 months. Sixty-four patients with prostate
cancer were treated with curative intent at the Medical
University of South Carolina between January 1995 and
December 1998. Patients with T4, metastatic and recurrent
tumors after prostatectomy were excluded. The majority of
the patients were treated with the same technique. These
patients were treated with ﬁve ﬁelds: two lateral, one ante-
rior, and two posterior oblique ﬁelds. Initially, a dose of 72 or
76 Gy was given depending on prognostic factors (stage,
PSA and Gleason score). Because all treatments have been
well tolerated with minimal toxicity, the dose was escalated
to 76 and 80 Gy. The delivered dose to the planning target
volume (PTV) for each group is shown in Table 1. An extra
margin from the PTV to the block was taken to get at least the
95% isodose line around the PTV. Treatment was given 5
days a week in 2 Gy per fraction. We outlined the PTV,
rectum and bladder on computed CT scan images taken
every 3 mm. The caudal border of the rectum was set at
9 mm cranial from the most caudal part of the anus. The
cranial border of the rectum was set at the rectosigmoid ﬂex-
ure. Bladder and rectal volumes were derived from dose–
volume histograms.
For assessment of early or late radiation side effects, blad-
der and bowel toxic effects were scored by use of the standard
Radiotherapy and Oncology Group (RTOG) criteria [3].
Diarrhea is deﬁned as frequent loose bowelmovements with-
out associated rectal irritation (tenesmus). Tenesmus is
deﬁned as rectal irritation or urgency. Cystitis is deﬁned as
irritative bladder symptoms such as frequency and dysuria.
The grades are as follows: Grade 0¼ no symptoms; grade
1¼minor symptoms requiring no treatment; grade 2¼
symptoms that respond to simple outpatient management
and do not affect lifestyle (performance status); grade 3¼
distressing symptoms that affect lifestyle andmaynecessitate
hospital admission for diagnosis or minor surgical interven-
tion (e.g. uretral dilation); grade 4¼major surgical interven-
tion (e.g. laparotomy, colostomy, cystectomy or long stay in
hospital; grade 5¼ fatal complications. Grades 1 and 2 rectal
bleeding is deﬁned as incidental and intermittent bleeding,
not requiring admission to the hospital or a blood transfusion,
respectively. Grade 3 rectal bleeding is deﬁned as bleeding
which requires admission to the hospital or a blood transfu-
sion. RTOG data were gathered retrospectively. Impotence
was not scored because many patients received hormonal
treatment during and after the radiotherapy for at least 1
year. Statistics were done with t-test. The patients were
seen every 3 months for the ﬁrst 2 years and every 6 months
thereafter. Late complicationswere scored if the patient had a
follow-up longer than 7 months. Ten patients were lost to
follow-up or had a follow-up shorter than 200 days. The
mean follow-up of the remaining 54 patients was 27 months.
The patients were divided into two groups: #72 Gy (Group
A) and $76 Gy (Group B). Groups A and B had a mean
follow-up of 32 months (10–49 months) and 22 months (7–
43 months), respectively. The patients were always seen on
the same day of the week, however, on request of the patient,
they could be seen on another day too. The side effects were
written on a follow-up sheet in the chart with dose and time at
which they occurred. Prescribed medication, reason of
prescription as well as the generic name and dose of
prescribed drug or examinations were registered too.
3. Results
3.1. Acute complications
Sixty-four patients were treated, 30 to a dose of 72 Gy, 15
Table 1
Dose (Gy) to the PTV
Dose escalation Prognosis P1 1 cm M P1 V1 1 cm M P1 1 cm M P1 0.5 cm M Total dose
No Favourable 50 22 72
Unfavourable 50 26 76
Yes Favourable 50 26 76
Unfavourable 50 20 10 80
P, prostate; V, seminal vesicles; M, margin.
Table 2
Patient characteristics
# 72 Gy $ 76 Gy
Number of patients 30 34
Mean age (years) 68 69
Stage
T1a 0 1
T1b 1 0
T1c 8 4
T2a 10 9
T2b 6 4
T2c 4 7
T3 1 9
Gleason score
2 to 3 2 0
4 to 7 27 28
8 to 10 1 6
PSA
,10 22 12
.10 8 22
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to a dose of 76 Gy and 19 to a dose of 80 Gy. Baseline
characteristics of the two groups are shown in Table 2. No
patients experienced a grade 3 or greater complication.
Therefore, we investigated the minor grades 1 and 2 compli-
cations. Acute rectal side effects were seen in 20 and 27% of
the patients in Groups A and B, respectively (Table 3).
Grades 1 and 2 side effects in Group A were seen in 10%
of the patients. For Group B 9% had grade 1 side effects and
18% had grade 2 side effects. Grade 2 diarrhea was only
seen in 10 and 15% for Groups A and B, respectively. These
symptoms were seen at a mean dose of 43 Gy for Group A
and 35 Gy for Group B (Table 4). These patients usually
reported ﬁrst a mild diarrhea, not requiring medication at a
mean dose of 39 and 32 Gy for Groups A and B, respec-
tively. No acute rectal grade 3 or 4 toxicity was seen.
Minor acute urinary side effects were seen in 63 and 71%
of the patients in Groups A and B, respectively (Table 5).
There were 30% grade 1 and 33% grade 2 side effects in
Group A. For Group B, 24% had grade 1 side effects and
47% had grade 2 side effects. Grade 2 dysuria was seen in
30% of the patients in Group A and in 24% of Group B.
Medication was prescribed at a mean dose of 46 and 42 Gy
for Groups A and B, respectively (Table 6). Seven percent
of Group A and 35% of Group B patients had grade 2
frequency. At a mean dose of 29 Gy for Group A and at
46 Gy for Group B, medication was prescribed. In both
groups, only grade 1 urgency was seen. It occurred in 3
and 6% of the patients in Groups A and B, respectively.
3.2. Irradiated volumes
The calculated rectal volumes for the acute rectal symp-
toms were of the same magnitude for the low doses but
diverted for greater doses (Table 7). Patients without symp-
toms had a mean rectal volume of 26 cm3 receiving 40 Gy or
more. The mean rectal volume for RTOGs 1 and 2 were 34
and 32 cm3, respectively. However, at a rectal dose of 70 Gy
or more, the difference between these groups was much
more different. In the RTOG 0 group the mean rectal
volume was 8.3 cm3: for RTOG 1 this was 14.6 cm3 and
for RTOGs 2 this was 15 cm3. When the RTOGs 1 and 2
complications were combined, the irradiated volume was
14.8 cm3 and signiﬁcantly different when compared with
RTOG 0 ðP ¼ 0:034Þ. The same trend was seen when we
looked at the patients with acute diarrhea. Patients without
diarrhea had a mean rectal volume receiving 70 Gy or more
of 8.5 cm3. However, patients with RTOG 2 diarrhea had a
mean rectal volume of 16.5 cm3 ðP ¼ 0:042Þ. With rectal
doses of 75 Gy or more, patients with no diarrhea had a
mean volume of 3.9 cm3. For the same dose level, RTOG
2 patients had a mean volume of 10.9 cm3 ðP ¼ 0:049Þ. The
percentage of irradiated rectum showed similar results
which are shown in Table 8.
The dysuria and frequency were not dose–volume related.
Larger irradiated bladder volumes per dose level were found
within the RTOG 0 group compared with the RTOGs 1 and
2 groups. When patients were grouped according to RTOG
bladder symptoms, no correlation in side effects, dose and
volumes were found (Table 9).
3.3. Late complications
No grade 3 or 4 late rectal or bladder symptoms were
seen. Four patients (7%) had late grade 1 rectal toxicity.
Two patients complained of temporary mild diarrhea that
resolved without medication. Occult fecal blood was found
in two other patients for a short period, which resolved
spontaneously, and sigmoidoscopy was not required. Two
patients (4%) had grade 2 toxicity due to rectal bleeding but
sigmoidoscopy could not ﬁnd a cause. Four other patients
had red blood loss per anus and underwent sigmoidoscopy:
one patient was diagnosed with rectal cancer, another with
polyps and diverticulosis, and two patients with hemor-
rhoids. Hospital admissions or blood transfusions were
never required.
Grade 1 late urinary complications were found in two
patients (4%): one patient complained of temporary dysuria
Table 3
Percentage of acute rectal side effects with corresponding grade
Dose (Gy) Grade Tenesmus (%) Diarrhea (%) Total (%)
#72 Grade 0 93 87 80
Grade 1 7 3 10
Grade 2 0 10 10
$76 Grade 0 85 79 73
Grade 1 12 6 9
Grade 2 3 15 18
Table 4
Mean dose at ﬁrst appearance of acute rectal side effects
Dose (Gy) Grade Tenesmus
(Gy)
Diarrhea
(Gy)
Total
(Gy)
#72 Grade 1 (symptoms) 34 20 29
Grade 2 (symptoms) 0 39 39
Grade 3 (medication) 0 43 43
$76 Grade 1 (symptoms) 43 57 47
Grade 2 (symptoms) 32 32 32
Grade 3 (medication) 32 36 35
Table 5
Percentage of acute bladder side effects with corresponding grade
Dose (Gy) Grade Frequency
(%)
Urgency
(%)
Dysuria
(%)
Total
(%)
#72 Grade 0 90 97 40 37
Grade 1 3 3 30 30
Grade 2 7 0 30 33
$76 Grade 0 34 94 55 29
Grade 1 21 6 21 24
Grade 2 35 0 24 47
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and haematuria, another complained of urgency and
frequency. Two patients (4%) had grade 2 side effects:
one complained of moderate urgency and frequency and
required medication, the other developed dripping of
urine. A ﬁfth patient complained also of frequency but
urine analysis showed an infection.
No correlation between dose–volumes and late side
effects could be found.
4. Discussion
4.1. Rectal volume
Rectal volumes are reported in mean cm3 as well as in
percentage of rectal volume. We think that absolute
volumes are of more value than percentage, because abso-
lute volumes do not account for inter- and intrapatient varia-
tions in the rectal deﬁnition. The transition of the sigmoid to
the rectum is a surgical deﬁnition and cannot be seen on CT
scan. For this reason, we chose to draw the rectum from the
last sigmoid ﬂexure (rectosigmoid ﬂexure) until 9 mm from
the anus. We only used one treatment planning CT scan a
day. This results in an estimation of the real rectal volume
because the rectal volume changes day by day and decreases
over time. A ﬁlled rectum will have an overestimation of the
irradiated rectal volume, an empty rectum an underestima-
tion [10]. Some authors give a suppository to the patients
just before the treatment to empty the rectum. However, the
advantage of this has not been shown. The use of the rectum
wall volume is described too, because there is less variation
in volume due to the rectal ﬁlling [10]. However, a different
rectum wall thickness has been used according to the rectal
ﬁlling, but also a constant thickness has been assumed
[10,25].
4.2. Acute rectal complications
We have demonstrated that relatively high doses can be
given without acute grade 3 or 4 toxicity during the treat-
ment. Despite the high doses delivered, the patients had only
minor grade 1 or 2 complications. Even with doses up to
80 Gy only 3 of the 19 patients had acute grade 2 rectal side
effects. More side effects were seen in Group B. When the
high dose volumes per group were compared, a greater
mean irradiated rectal volume was found for the RTOG 2
scores then for the RTOG 0 scores. When Group B was
compared with Group A, the irradiated rectal volumes
were greater in Group B. So the higher the dose, the more
the volume was treated and the more side effects were
reported.
By using the absolute volumes we found that a mean
rectal volume of 11 cm3 receiving a dose of 75 Gy or
more can cause diarrhea-requiring medication. However,
some patients had a larger volume than this and had no
symptoms. This can be explained by an overestimation of
the rectal volume due to rectal ﬁlling during the treatment
planning CT scan or by interpatient sensitivity differences.
Storey et al. [20] and Pollack et al. [15] found no dose–
volume correlation for the proportional volumes treated to
60 Gy or greater and no difference in the incidence of acute
rectal symptoms when treated to 70 or 78 Gy. The fact that
Table 6
Mean dose at ﬁrst appearance of acute bladder side effects
Dose (Gy) Grade Frequency (Gy) Urgency (Gy) Dysuria (Gy) Total (Gy)
#72 Grade 1 (symptoms) 36 22 37 35
Grade 2 (symptoms) 29 / 38 36
Grade 2 (medication) 29 / 46 43
Grade 1 (symptoms) 50 68 45 50
$76 Grade 2 (symptoms) 36 / 28 33
Grade 2 (medication) 42 / 41 42
Table 7
Mean irradiated rectal volumes (cm3 and SD) with associated RTOG score
or acute symptom (diarrhea) and associated dose
Dose (Gy) RTOG 0 RTOG 2 RTOG 11 2
cm3 SD cm3 SD cm3 SD
RTOG 60 15 9 21 22 21 20
70 8 7 15 20 15* 16
75 4 6 10 20 8 16
Acute diarrhea 60 15 9 23 23 22 20
70 9 7 17* 21 15 19
75 4 6 11* 21 10 18
* Signiﬁcantly different when compared with RTOG 0 ðP , 0:05Þ.
Table 8
Mean percentage of irradiated rectal volume (% and SD) with associated
RTOG score or acute symptom (diarrhea) and associated dose
Dose (Gy) RTOG 0 RTOG 2 RTOG 11 2
% SD % SD % SD
RTOG 60 18 10 26* 17 25* 15
70 10 9 18* 16 17* 14
75 5 8 10 17 7 14
Acute diarrhea 60 18 9 28* 18 24 16
70 10 8 20* 17 17* 15
75 5 8 12 18 10 15
* Signiﬁcantly different when compared with RTOG 0 ðP , 0:05Þ.
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both groups were ﬁrst treated by using a four-ﬁeld box
technique to a dose of 46 Gy can have caused this result.
This corresponds with our ﬁndings that grade 2 side effects
are reported at a mean dose of 35–43 Gy for Groups A and
B, respectively. Leibel et al. [11], who used almost the same
beam directions as we did, found the same acute rectal
symptom incidence for the whole study: 14%. He also did
not ﬁnd grade 3 or 4 acute rectal symptoms. Shu et al. [19]
treated 44 patients to a dose of 82 Gy with 3D conformal
and intensity modulated radiotherapy. He reported acute GI
symptoms in 34% of the patients. However, 32% of the
patients received whole pelvis treatment that signiﬁcantly
increased the incidence of acute toxicity.
4.3. Late rectal complications
Despite the high doses that were delivered to the prostate,
late side effects in this study are low. However, with a
longer follow-up this may still increase, because the mean
follow-up for Groups A and B was 32 and 22 months,
respectively. Late GU side effects occur at a mean time of
22 months, while late rectal bleeding is seen at a mean time
of 14 months [18] or at a median time of 17 or 18 months
[6,23]. Considering these data, the late toxicity of our
patients probably will increase more in Group B than A.
On the other hand, the low late toxicity can be explained
by the low irradiated rectal volumes. Dearnaley et al. [4]
reports 37% late rectal RTOG 1 side effects for the patients
treated with conformal radiotherapy, which is higher than
this series despite much lower doses. In his conventional
group, 56% of the patients had late rectal RTOG 1 side
effects. The RTOG 77-06 study [13] reported bowel toxicity
caused by doses up to 70 Gy such as diarrhea (15%), proc-
titis (11%), rectal stricture (9%), rectal bleeding (20%) and
rectal ulcer (2%) when they were treated with a pelvis ﬁeld
and boost to the prostate. Sandler et al. [17] found a 3% risk
of a grade 3 or 4 complication at 3 years. Two-third of his
patients received a pelvic ﬁeld with a maximal dose of
71 Gy. Teshima et al. [23] found a 3 year actuarial rate of
grade 2 rectal bleeding of 11% in patients who received
,73 Gy and 22% in those who received 73 Gy with confor-
mal radiotherapy. With our doses up to 80 Gy no rectal
ulcers or rectal strictures were diagnosed. This provides
evidence that the volume of irradiated tissue is an important
determinant of toxicity. Wachter et al. [24] found an average
volume of 26% at a dose of 66 Gy to cause late rectal side
effects. Storey et al. [20] reported a signiﬁcant increase in
late rectal complications when more than 25% of the rectum
received 70 Gy or more. Hartford et al. [6] reported rectal
bleeding if 70% of the anterior rectal wall received 60
Cobalt Gray Equivalent. We were not able to demonstrate
a dose–volume effect for patients with late rectal side effects
versus no side effects, probably due to the low incidence of
late complications. However, both Schultheiss et al. [18]
and Jackson et al. [8] were able to ﬁnd dose–volume rela-
tionship for late rectal bleeding. Boersma et al. [1] found
severe rectal bleeding in patients where more than 40 and
30% of the rectal wall volume received at least 65 and
70 Gy, respectively.
4.4. Acute bladder complications
No grade 3 or 4 acute bladder toxicity was reported.
Grade 2 acute urinary symptoms were seen in 33 and 47%
for Groups A and B, respectively. The results of the low
dose group are in the same range as Leibel et al. [11]
reported. He found a grade 1 incidence of 44% and grade
2 incidence of 25%, probably because his doses were vary-
ing from 65 to 75 Gy. Koper et al. [9] found a lower grade 2
toxicity (16%), probably due to the lower dose (66 Gy).
Although, he reported a great difference in irradiated blad-
der volume between the conventional and conformal group,
no correlation was found. RTOG scores were split up into
frequency and dysuria but these toxicities were not bladder
volume dependent. Also Leibel et al. [11] did not ﬁnd a
toxicity volume correlation. The lack of this correlation
can be explained by the inﬂammation of the prostatic
urethra or by bladder volume variation. Lebesque et al.
[10] found an intrapatient bladder volume variation of
33% and a bladder wall volume variation of 17% and
concludes that the bladder wall volume is the only relatively
constant volume during treatment. Nocturia was not scored
because many patients had this symptom before the start of
the treatment. Grade 2 urinary symptoms were reported at a
dose of 28–42 Gy, but most of the patients refused medica-
tion at that time, but requested the medication 1 or 2 weeks
later. This explains why the medication was prescribed at a
higher dose when compared with the RTOG 1 symptoms.
4.5. Late bladder complications
Only four patients of the 54 (7%) can be classiﬁed as
having some minor late bladder symptoms. This number
can increase due to our short follow-up. One patient
complained of dripping but he was more than 70 years
old. Since incontinence is age related and more frequent
in patients older than 65 years, it is not clear that inconti-
nence is treatment related [22]. Urinary symptoms were not
related to dose or the volume of irradiated bladder. Dearna-
ley et al. [4] found no signiﬁcant difference in late grade 1 or
higher urinary side effects with conformal versus conven-
tional treatment and Pollack et al. [15] did not ﬁnd a corre-
lation between volume and toxicity. This suggests that
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Table 9
Mean irradiated bladder volumes (cm3) with associated RTOG score for
dysuria and dose
Dose (Gy) RTOG 0 RTOG 1 RTOG 2 RTOG 11 2
Dysuria 60 30 22 25 24
70 19 12 16 15
75 9 5 9 7
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urinary symptoms are most likely related to urethritis and
not to bladder irradiation.
In summary, with a mean follow-up of 27 months, we
have seen no grade 3 or 4 acute or late urinary or rectal
toxicity with doses as high as 80 Gy. We have demonstrated
a dose–volume relationship with grade 2 acute rectal side
effects, which were seen in 10 and 18% of the patients in
Groups A and B. They were observed at a mean dose of
38 Gy. Acute grade 2 urinary symptoms were 33 and 47%
for Groups A and B, respectively, and were seen at a mean
dose of 43 Gy. No dose–volume relationship for bladder
symptoms was seen. Minor late rectal and bladder side
effects were seen in ten of the patients but none of these
required admissions to the hospital or blood transfusions.
No correlations between dose–volumes and late side effects
could be found.
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THE POSITION AND VOLUME OF THE SMALL BOWEL DURING
ADJUVANT RADIATION THERAPY FOR RECTAL CANCER
JOOST J. NUYTTENS, M.D., JOHN M. ROBERTSON, M.D., DI YAN, D.SC., AND
ALVARO MARTINEZ, M.D., F.A.C.R.
Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, MI
Purpose: The rate of small bowel toxicity from adjuvant pelvic radiation therapy (RT) for rectal cancer has been
reported to be lower for patients treated preoperatively (Preop). This was probably due to a lesser volume of
irradiated small bowel; however, studies of postoperative treatment reported that patients with an abdomino-
perineal resection (APR), who likely have the largest volume of small bowel in the pelvis, had less acute and
chronic toxicity than those with a low anterior resection (LAR). In this study, three-dimensional treatment
planning techniques were used to characterize the position and volume of small bowel in the pelvis and compare
these to repeat studies obtained during the typical 5-week course of treatment to attempt to explain the above
observations.
Methods and Materials: Treatment planning CT scans were obtained in 30 patients with rectal cancer (10 Preop,
10 LAR, 10 APR), including 12 patients with weekly CT scans during RT (65 scans). The position of the small
bowel was measured by the distance to the nearest small bowel from the bones of the posterior pelvis and by the
volume of small bowel within four anatomically deﬁned regions of the pelvis. The motion of the small bowel was
expressed as the standard deviation of the small bowel position measured with both the distance and the volume
in the 12 patients with repeat studies.
Results: Contrast-containing small bowel was found an average 2.9 cm more anterior than small bowel without
contrast below the sacral promontory. The position of the small bowel in Preop patients was signiﬁcantly more
anterior (p< 0.01) with less volume (p< 0.04) in the pelvis than postoperatively treated patients. The small bowel
was also more anterior for patients with an LAR vs. APR (p< 0.03) but with similar volume in all pelvic regions.
Small bowel motion, expressed as the standard deviation of the distance from the bones of the posterior pelvis
to the closest small bowel, was 2.9 cm, 1.4 cm, and 0.2 cm for the Preop, LAR, and APR group, respectively. The
LAR group had a considerable degree of motion in the posterior pelvis. Increased bladder volume was associated
with reduced small bowel volumes, although this beneﬁt decreased during treatment.
Conclusion: Because treatment planning CT scans can detect small bowel that does not contain contrast, they
may be more accurate than the traditional small bowel series. The Preop patients had signiﬁcantly less pelvic
small bowel supporting the clinical observation of better tolerance to therapy. The higher small bowel toxicity
reported for LAR vs. APR patients may be explained by the greater variability of both the position and volume
of the small bowel in the posterior pelvis for LAR patients. This ﬁnding suggests that a single planning study may
not be accurate for the block design used for boost treatment of LAR patients. Bladder-ﬁlling techniques were
useful for Preop and LAR but not APR patients, and decreased in beneﬁt over time. This study suggested that
treatment planning CT scans were more useful than a small bowel series and that more than one treatment
planning CT may be obtained in any patient receiving > 45 Gy for rectal cancer. However, further research will
be necessary to determine the optimal timing and total number of repeat studies. © 2001 Elsevier Science Inc.
Small bowel, Radiotherapy, Toxicity, Rectal cancer, Motion.
INTRODUCTION
Diarrhea is a common side effect of adjuvant radiation
therapy (RT) combined with chemotherapy for carcinoma
of the rectum (1–5). In a prospective four-arm randomized
trial of adjuvant postoperative chemoradiotherapy, acute
severe diarrhea occurred in 15–39% of subjects and par-
tially accounted for the approximately 20% of patients that
failed to complete therapy (4). If failing to receive the
complete treatment decreases the efﬁcacy of therapy, then
reducing the rate of acute diarrhea may lead to an overall
improvement in therapeutic outcome. Preoperative radio-
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chemotherapy has been associated with a lower incidence of
Grade 3 diarrhea than postoperative RT (3, 6–10), pre-
sumably due to an absence of ﬁxed bowel loops within the
pelvis (8). This proposed mechanism was supported by
studies in rectal cancer and gynecologic cancers that have
found ﬁxed small bowel in 29% and 65% of patients,
respectively (11, 12). The presence of a ﬁxed bowel loop
would have two consequences. First, it would ensure that
the ﬁxed portion of small bowel received all of the radiation
dose, in contrast to mobile small bowel, which may move
outside of the irradiated volume. Second, a ﬁxed portion
may tether the small bowel within the pelvis, which could
lead to an increase in the total volume of small bowel
irradiated. The only study that compared the volume of
small bowel irradiated between preoperative and postoper-
ative RT found a signiﬁcant difference, suggesting that this
hypothesis was correct (8).
The relationship between the volume of small bowel
irradiated and the development of diarrhea is well recog-
nized (8, 13, 14) but was not well quantiﬁed until recently
(15). Nevertheless, exclusion of the small bowel from the
pelvis to improve the tolerance to therapy has been the
subject of a considerable number of research efforts. These
have ranged from surgical techniques, such as omental
slings, pelvic mesh, and tissue expanders, to radiation tech-
niques, such as a prone cradle with a depressed area for
small bowel exclusion (“belly board”), bladder distension,
and multiﬁeld arrangements (16, 17). In fact, the use of
preoperative treatment could be viewed as another method
to exclude the small bowel from the pelvis. The success of
these maneuvers has typically been determined using a
small bowel series at the time of simulation, although three-
dimensional treatment planning has been used to demon-
strate the superiority of a “belly board” (17–19).
Recommendations for treatment planning for adjuvant
pelvic RT have included a single small bowel study (16).
However, the small bowel is a mobile structure and, other
than at the root of the mesentery and any surgically adherent
areas, would be expected to change in position during the
course of treatment. One section of small bowel is essen-
tially indistinguishable from another and, short of surgically
marking segments, the only method available to assess
motion would be to compare the position and volume of
small bowel within the pelvis over time. There are three
reports that have addressed the variability of the position of
the small bowel during a course of RT. All three calculated
the volume of small bowel using the outline of the contrast
seen with a small bowel series, and the variability was
judged using a single repeat small bowel series during RT.
One study found that the beneﬁt of bladder ﬁlling was lost
midway through therapy in 18 people receiving RT for
rectal cancer (11). The other two reports included patients
with other pelvic malignancies and differed in their conclu-
sions. One report studied 50 individuals and found that there
was an average increase in small bowel volume by 20%
after 45–50 Gy but did not supply further data (13). The
other studied 12 patients, 4 of whom had rectal cancer, and
found no alteration in small bowel mobility after 39.6–46
Gy (20).
The study reported here used treatment planning com-
puted tomographic (CT) scans with oral contrast to measure
the position and the volume of the pelvic small bowel. This
method is inherently more accurate than the traditional
small bowel series and offers the possibility of volumetric
studies. We hypothesized that individuals treated with pre-
operative RT would have a different position and volume of
the small bowel than those treated with postoperative RT. A
number of the individuals also had CT scans in the treat-
ment position obtained on a weekly basis. These studies
were used to determine the possible range of motion by the
small bowel and the impact of the bladder and colon on the
small bowel position.
METHODS AND MATERIALS
The treatment planning CT scans were reviewed for 30
consecutive patients with rectal cancer. All scans were
obtained using a helical CT scanner with a 0.5 cm slice
thickness and included a minimum visualization of the
entire treated volume of the pelvis. The postoperative group
consisted of 10 patients with abdominoperineal resections
(APR) and 10 with low anterior resections (LAR). Nine
patients were treated with preoperative RT (Preop). One
patient was treated with postoperative pelvic RT after a
wide local excision (WLE) of a T2 low rectal primary
tumor. Because this patient had no intraabdominal surgery,
he was included with the preoperative RT group for pur-
poses of analysis. Oral contrast was given between 11⁄2 and
2 h (11) before the treatment planning CT scan in 29
patients. All were placed prone on a vacuum bag cradle with
a depressed area for small bowel exclusion but rigid foam
beneath the pubis and the chest. Patients were given full
bladder instructions before the treatment planning CT scan.
On each CT slice, distances were measured from the
anterior border of L5 and the sacrum to the closest small
bowel in the midline and 2 cm to both the left and right of
the midline (Fig. 1). These distances were obtained for both
any small bowel and for contrast-containing small bowel.
Measurements of the most caudal position of the small
bowel were also obtained in the cranial-caudal dimension.
Student’s t test was used to compare the characteristics of
small bowel position between and within the three groups
(APR, LAR, and Preop).
Volumetric measurements were obtained by dividing the
pelvis into four regions based, in part, on a typical treatment
ﬁeld (Fig. 2). The superior border of the suprapelvic region
was the top of L5. The anterior border of the suprapelvic
and anterior midpelvic region was placed 5 cm anterior to
the sacral promontory with the posterior border at the sacral
promontory. The sacral promontory also was the border
between the anterior and central midpelvic regions. The
border between the central midpelvic and the posterior
midpelvic regions was halfway between the sacral promon-
tory and the sacrum. The posterior border of the posterior
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midpelvic region was the posterior sacrum. The inferior
border of the midpelvic regions was 1 cm above the sym-
physis pubis. Mean volume differences in each of the four
regions between the different surgical groups were com-
pared using Student’s t test.
Twelve of the patients (2 APR, 6 LAR, 3 Preop, and 1
WLE) also had weekly CT scans in the treatment position
with small bowel contrast. There were 4–7 CT scans per
patient (median of 5) depending on the length of treatment
and patient cooperation. The scans were registered using the
bones of the pelvis, and the organs of interest were outlined
on each CT slice by a single physician (J.J.N.), allowing a
subjective comparison of studies within the same patient by
overlaying digitally reconstructed radiographs. Objective
motion of the small bowel was calculated using both the
distance to small bowel from the posterior bones and the
volume of small bowel within each deﬁned region of the
pelvis. The distance to the nearest small bowel on each CT
slice was subtracted from the mean distance for the indi-
vidual patient and the standard deviation (SD) was calcu-
lated. Motion was also expressed using the volumetric data
by subtracting the volume per region on each weekly CT
scan from the mean volume for each patient and determin-
ing the SD from these data. The coefﬁcient of variance was
calculated by dividing the SD by the mean.
The relationship of bladder ﬁlling to small bowel position
was examined using both the distance measurement and
volume measurements. First, the height of the small bowel
within the pelvis was measured as the most inferior position
of the small bowel. This measurement was compared to the
normalized bladder volume to examine if any relationship
existed between the small bowel position and the bladder
volume. The small bowel height was also recorded in rela-
tionship to the bladder volume as a function of treatment
time. Second, the volume was used to examine for correla-
tions between the bladder volume and small bowel volume
within the deﬁned regions.
RESULTS
Small bowel visualization
Incomplete visualization of the small bowel was found in
17 of the 29 patients with small bowel contrast for the initial
treatment planning CT (Fig. 3). Below the sacral promon-
tory, the most posterior portion of contrast-containing small
bowel was an average of 2.9 cm more anterior to the
noncontrast-containing small bowel. Above the sacral
promontory, the average distance was 1.5 cm, again with
noncontrasted small bowel more posterior. In 8 patients, the
most inferior CT slice did not contain small bowel contrast,
leading to an average cranial-caudal mismatch of 1.8 cm.
For the remainder of this analysis, the entire small bowel
was used without regard to contrast.
Small bowel position
Measurement of the distance from the posterior bones of
the pelvis to the closest portion of small bowel found
signiﬁcant differences in the position of the small bowel
inferior to the sacral promontory among the three patient
groups (Fig. 4). From the sacral promontory until 5 cm
Fig. 1. Two examples of the distance measurement performed from the posterior bones of the pelvis at L5 (a) and the
midsacrum (b).
Fig. 2. Division of the pelvis into the separate regions, referred to
as the suprapelvis (A), anterior midpelvis (B), central midpelvis
(C), and posterior midpelvis (D).
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Fig. 3. A digitally reconstructed radiograph showing the position of opaciﬁed (purple) vs. all small bowel (blue).
Fig. 4. The mean distance from the posterior bones of the pelvis (diamond symbols) to the closest small bowel in the
midline for low anterior resection (triangles), abdominoperineal resection (circles), and preoperative (squares) patients.
The sacral promontory was placed at slice position 22 for all measurements.
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inferior to the promontory, midline measurements were
signiﬁcantly different (p  0.01) between the Preop and
both the APR and LAR groups. The APR and LAR groups
were also signiﬁcantly different from each other (p  0.03)
for most of the distance inferior to the promontory (except
between 6 and 7.5 cm inferior to the promontory). On the
right side of the pelvis, the distance to small bowel was
signiﬁcantly different between APR vs. Preop patients (p 
0.01), inferior to the sacral promontory and vs. LAR pa-
tients from 1.5 to 7 cm inferior to the sacral promontory
(p  0.02). Differences between the LAR and Preop pa-
tients were only found caudally from 2.5 cm inferior to the
sacral promontory (p  0.01). The distance to small bowel
on the left was signiﬁcantly different for APR and LAR vs.
Preop (p  0.04).
The observation of any small bowel within the pelvis was
markedly different between the different surgical groups
(Table 1). In 6 of 10 APR patients, the small bowel was
found at 8 cm inferior to the promontory, compared to only
1 of 10 Preop patients.
Volumetric analysis found no difference in small bowel
volume in the suprapelvic region (Table 2). In the anterior
midpelvic region, the mean volume of small bowel for both
the APR and LAR group was nearly equal, although only
the LAR group was signiﬁcantly different from the Preop
group (p 0.03). Together, the postoperative patients (APR
plus LAR) had a signiﬁcantly larger volume of small bowel
in the anterior midpelvis than the Preop group (p  0.02).
The APR group had signiﬁcantly more small bowel in both
the central (p  0.002) and posterior midpelvis (p  0.02)
than the Preop group. In fact, all of the APR patients had
small bowel in the posterior midpelvis, whereas no small
bowel was found in this region in any of the Preop group.
Small bowel motion
Comparison of the digitally reconstructed radiographs
found considerable differences in the position of the small
bowel during a course of treatment (Fig. 5). The Preop
group had the largest degree of motion in the anterior to
posterior dimension. At 5 cm inferior to the sacral promon-
tory, the average standard deviation was 2.7 cm, 1.4 cm, and
0.2 cm for the Preop, LAR, and APR groups, respectively
(Table 3). The LAR group also had a considerable amount
of motion, with an average SD of up to 3.1 cm at 8 cm
inferior to the sacral promontory. The smallest degree of
motion was found below the sacral promontory in the APR
group, which suggested ﬁxation against the sacrum. The
average standard deviations of the movement to the left and
right of the midline were similar (data not shown). In the
craniocaudal dimension the average SD was 1.6 cm, 1.1 cm,
and 0.8 cm for the Preop, LAR, and APR groups, respec-
tively.
Volumetric analysis found that the average standard de-
viation of the small bowel volume in the anterior midpelvis
was similar for all three patient groups (Table 4). However,
because the Preop group had less overall small bowel, the
coefﬁcient of variance for the preoperative patients was
three times higher than for the postoperative patients. Over-
all, the highest coefﬁcient of variance was found in the
posterior midpelvis for the LAR group (350%) and in the
central midpelvis for the Preop group (225%), suggesting
that any single measurement of the small bowel position,
such as the traditional small bowel series for treatment
planning, has a large probability of inaccuracy in these
regions.
Bladder volume vs. small bowel
There was a relationship found between the most inferior
small bowel position in the cranial-caudal dimension on
each CT scan and the bladder volume, with a correlation
coefﬁcient of 0.59 (p  0.0005) and 0.7 (p  0.0003) for
LAR and Preop groups, respectively (Fig. 6). No correlation
was found for the APR group (r  0.11, p  0.7). There
was a trend toward reduced bladder volumes with a more
inferior position of the small bowel during the last 3 weeks
of treatment (Fig. 7). There was no correlation between the
bladder volume and the position of the small bowel in the
anterior to posterior dimension.
The mean volume of the bladder in the anterior midpelvic
region was 84 cm3 for APR and LAR patients and 95 cm3
for the Preop patients. In the central midpelvis, the bladder
volume was 25 cm3 for the APR group, 8 cm3 for the LAR
group, and 5 cm3 for the Preop group, but without a signif-
icant difference. In the anterior midpelvic region, the blad-
der volume and small bowel volume were correlated (r 
0.53, p  0.0001), and a full bladder reduced the small
bowel volume by 64%. This relationship was present for
Table 1. The frequency (%) of small bowel at the designated
level
Surgery
cm inferior to the sacral promontory
0 2 4 6 8 10
Preop 70 60 40 10 10 0
LAR 100 100 90 80 40 20
APR 100 100 100 90 60 10
Abbreviations: Preop  patients receiving preoperative RT;
LAR  low anterior resection; APR  abdominoperineal resec-
tion.
Table 2. The position of the small bowel within the pelvis,
expressed as the mean volume (cm3) of small bowel per region
as deﬁned in Figure 2
Region within
the pelvis
Mean volume (cm3)
APR LAR APR  LAR Preop
Suprapelvis 43 40 41 37
Anterior midpelvis 149 159* 157* 46*
Central midpelvis 74* 50 56* 4*
Posterior midpelvis 14* 6 8 0*
* p-value  0.05 for Preop versus APR, LAR, or APR  LAR
group.
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both the LAR group (r  0.58, p  0.0005; 48% small
bowel reduction) and the Preop group (r  0.59, p  0.01;
140% small bowel reduction). In the central midpelvic
region there was a good correlation (r  0.57; p  0.001)
between the small bowel volume and the volume of the
bladder plus the colon. When the bladder and colon were
fully present, there was a 130% reduction in small bowel
volume. There was no correlation between the bladder vol-
ume in the anterior midpelvis and the small bowel volume
in the suprapelvis (r  0.01; p  0.9), suggesting that a full
bladder does not push the small bowel into this region.
DISCUSSION
It is impossible to directly compare the traditional small
bowel series to a treatment planning CT, as the contrast
requirements are different for each of the two studies. Al-
though the CT scan could be performed ﬁrst followed by
administration of additional oral contrast for the small
bowel series, the time delay required to allow the extra
full-strength barium to reach the small bowel would intro-
duce a potential source of variation. In this study, there was
no variation due to time as the position of opaciﬁed bowel
Fig. 5. Digitally reconstructed radiographs showing the maximum and minimum position of the small bowel observed
during a course of adjuvant pelvic RT. (a) A patient with an abdominoperineal resection, with the maximum position
shown in green, the minimum in red, and overlap shown as a combination of the two colors. (b) A patient with a low
anterior resection, with the maximum position shown in blue, the minimum in red, and the overlap in purple. (c) A
patient receiving preoperative treatment, with the maximum shown in blue, the minimum in yellow, and overlap in tan.
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on the CT scan was used to mimic the traditional small
bowel series. Unopaciﬁed small bowel was found in over
50% of the CT scans, with an average distance from opac-
iﬁed small bowel of over 1.5 cm. This difference was most
likely due to incomplete ﬁlling of the ileum despite the
administration of oral contrast at the recommended 11⁄2 to
2 h before the study (11). Because the ileum may be the
target organ for acute radiation enteritis (21, 22), inaccurate
visualization is especially concerning, and suggests that the
added expense of treatment planning CT scans was well
justiﬁed.
As hypothesized, the position of the small bowel in the
pelvis was signiﬁcantly more anterior and superior in the
preoperative group. Signiﬁcant differences were also found
in the volumetric analysis, providing objective evidence that
the preoperatively treated patients had less small bowel
irradiated than postoperatively treated patients. This ﬁnding
is in general agreement with a report that found a mean 462
cm3 of small bowel irradiated in postoperatively treated
patients compared to 212 cm3 in preoperatively treated
patients (8). However, in contrast to that report, we found a
considerably smaller volume irradiated in both groups, with
a mean of 262 cm3 and 87 cm3 for postoperative and
preoperative patients, respectively. Part of this difference
could have been due to minor disagreements in the ﬁeld
design at the anterior and superior border but the bulk of the
difference was probably due to the method used for mea-
surement. In our study, the small bowel was outlined on
each CT slice and three-dimensional treatment planning was
used. The other study used the outline of the opaciﬁed small
bowel seen on orthogonal simulation ﬁlms, which would
tend to overestimate the volume of small bowel. Regardless
of the differences between studies, this study provided more
evidence that preoperative treatment irradiates a signiﬁ-
cantly less volume of small bowel than postoperative treat-
ment.
Despite the common perception that preoperative treat-
ment is better tolerated, there is no current randomized
evidence of reduced Grade 3 diarrhea. The only published
randomized study of preoperative RT to 45–50 Gy vs.
postoperative RT found that the Grade 3 diarrhea rate was
39% for preoperative treatment and 23% for postoperative
treatment (2). This ﬁnding was considerably different from
multiple single-arm, single-institution studies of preopera-
tive RT to 45–50 Gy, that have reported severe diarrhea
rates of only 1–14% (3, 6, 7, 9, 10). A number of possible
reasons exist for the difference between the randomized and
nonrandomized studies, including the radiation therapy ﬁeld
design, beam arrangement, and chemotherapy agents used.
However, we believe that the discrepancy probably was due
to the different toxicity grading scales used. These deﬁni-
tions have ranged in precision from the absolute number (6,
7, 23) or an increase in the number of bowel movements in
24 h (24), to a subjective judgment that the toxicity was
“severe,” “ life-threatening,” or “intolerable requiring ther-
Table 3. Motion of the small bowel for 12 patients with weekly
treatment planning CT scans during treatment*
Inferior to sacral
promontory
Average standard deviation (cm)
APR LAR Preop
0 cm 1 1.1 1.5
2.5 cm 0.2 1 1.6
5.0 cm 0.2 1.4 2.7
7.5 cm 0.1 2.4 N/A
* The average standard deviation (cm) of the distance in the
midline from the posterior bones of the pelvis to the small bowel
is shown for each of the surgical groups of patients. Distances are
shown at a speciﬁed distance inferior to the sacral promontory.
Table 4. The motion of the small bowel within the pelvis, as expressed by the average standard deviation of the volume of small bowel
per region as deﬁned in Figure 2 and the coefﬁcient of variation
Region within the
pelvis
Standard deviation/Coefﬁcient of variation
APR LAR APR  LAR Preop
Suprapelvis 6/14 12/30 11/27 12/32
Anterior midpelvis 38/25 28/23 30/19 34/74
Central midpelvis 20/27 22/44 21/38 9/225*
Posterior midpelvis 4/29 21/350* 14/175* 0/0
* Coefﬁcient of variation was greater than 100%.
Fig. 6. The craniocaudal small bowel position vs. bladder volume
in preoperatively treated patients.
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apy” (1, 9, 10, 25). Thus, a preoperative patient with pre-
treatment diarrhea due to the tumor itself could be assigned
a high maximum toxicity grade in a study using the absolute
number of bowel movements per day but a low grade in a
study using an increase in the number of bowel movements
per day. Indeed, the authors of the randomized preoperative
vs. postoperative treatment study believed that pretreatment
diarrhea due to the unresected tumor was probably the
explanation for the discrepancy between the preoperative
and postoperative diarrhea rates found in the trial (2). This
question could be answered simply by obtaining pretreat-
ment symptoms, or comparing the weekly diarrhea assess-
ment to the timing of the RT, as patients with diarrhea due
to the tumor would be expected to exhibit a high diarrhea
grade at the start of treatment. The perception of improved
tolerance to preoperative treatment may be genuine, but not
measurable using toxicity scales that fail to account for
baseline function.
In fact, all of the toxicity grading scales for diarrhea can
be criticized. Scales that measure the maximum number of
stools in one day ignore the baseline bowel function and
overemphasize the single 24-h evaluation. Most ignore the
reversibility of symptoms with medications or diet modiﬁ-
cation. Those depending on “severe” or “life-threatening”
toxicity require a subjective decision on the part of the
treating physician, which is more difﬁcult to deﬁne in a
multi-institutional setting. The current Common Toxicity
Criteria deﬁnes Grade 3 diarrhea as an increase of greater
than or equal to 7 stools per day, or incontinence, or the
need for parenteral support (26). Although this scale can
account for pretreatment diarrhea, it ignores the reversibility
of symptoms with antidiarrheal medications and diet mod-
iﬁcation, and focuses on the single worst day of treatment
without regard to the length of time that symptoms are
present. With this deﬁnition, a patient experiencing nine
bowel movements in 24 h compared to the usual two bowel
movements would have Grade 3 toxicity even if symptoms
completely resolved by the following day using antidiar-
rheal medications and diet modiﬁcation, and the remainder
of treatment was accomplished without difﬁculty.
Between the two postoperative groups, APR patients had
a signiﬁcantly more posterior small bowel position but with
only minor differences in volume in the pelvic region com-
pared to the LAR patients. Other studies have also found no
difference in the volume of small bowel irradiated between
these two patient groups (27). This would suggest that
tolerance to treatment would be equal or, if anything, worse
for the APR group given the relationship between the vol-
ume irradiated and the development of acute small bowel
toxicity (15). However, the clinical evidence disagrees with
this prediction, ﬁnding that the rate of severe diarrhea was
actually worse for the LAR group (5). In a review of 96
patients treated with adjuvant postoperative RT and chemo-
therapy on a multi-institutional study, the rate of Grade 3
diarrhea was 30% vs. 13% for LAR and APR patients,
respectively (5). One explanation for this apparent disagree-
ment is that measurements of stool frequency were less
accurate after an APR, as the stool is collected in the stoma
bag. However, the risk of chronic bowel injury has also
been reported to be higher in LAR patients (28), and given
that chronic bowel injury is a more objective endpoint, this
evidence suggests that a real difference exists between these
patient groups.
Although our study included only 2 patients with an APR
and 5 with a LAR, some observations may help to explain
the greater toxicity in LAR patients. The distance measure-
ments suggested ﬁxation of the small bowel in the posterior
pelvis for the APR group, with a standard deviation of only
1 mm at 7.5 cm below the sacral promontory, compared to
3.1 cm for the LAR group at the same point. The volume
measurements within the posterior pelvis found that APR
patients had 14 cc of small bowel with a 4 cc standard
deviation whereas LAR patients had 6 cc of small bowel but
a 21 cc standard deviation. Together, these data suggested
that a single small bowel study obtained for treatment
planning may be accurate for APR patients, but would fail
Fig. 7. The bladder volume and lowest small bowel position over time for Preop and Postop patients.
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to completely deﬁne the overall possible position of the
small bowel in the LAR group. Thus, the block design for
any boost beyond 45 Gy was probably more accurate for
APR than LAR patients, and LAR patients may have inad-
vertently received a dose to the small bowel higher than that
intended. Further investigation including a larger number of
patients will be necessary, but these results suggest that
repeat treatment planning CT scans may be reasonable in
any patient in whom the planned dose of RT exceeds 45 Gy.
It does not, however, provide enough information regarding
the timing or total number of any repeat studies.
Bladder-ﬁlling techniques were helpful for both preoper-
ative and LAR patients, but not for those with an APR. This
beneﬁt was most evident in the anterior pelvic region, which
was the region with the largest volume of small bowel in all
groups. Although not usually within a treatment volume,
this region would be expected to receive exit dose from a
posterior to anterior treatment ﬁeld. Given that small bowel
toxicity was shown to be primarily dependent on the volume
of small bowel receiving over 15 Gy (15), reducing the
volume of the small bowel in the anterior region may have
an impact on the tolerance to therapy. However, there was
some evidence that this beneﬁt was lost over time, in
agreement with another study (11). The explanation for this
was not obvious. It was possible that patients were experi-
encing bladder, small bowel, or rectal irritation with in-
creased frequency and had difﬁculty performing the full
bladder instructions. However, it is also possible that the
treated subjects simply became less attentive to the full
bladder instructions, despite weekly reminders.
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THE VARIABILITY OF THE CLINICAL TARGET VOLUME FOR RECTAL
CANCER DUE TO INTERNAL ORGAN MOTION DURING
ADJUVANT TREATMENT
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ALVARO MARTINEZ, M.D., F.A.C.R.*
*Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, MI; †Department of Radiation Oncology,
Ghent University Hospital, Ghent, Belgium
Purpose: This study deﬁned the clinical target volume (CTV) for the adjuvant treatment of rectal cancer and
applied this deﬁnition to multiple CT scans obtained during the typical 5-week course of treatment to measure
the modiﬁcation to the CTV due to internal organ motion that would be needed to deﬁne the planning target
volume (PTV).
Methods and Materials: Ten patients with rectal cancer had weekly treatment planning CT scans during
adjuvant radiation therapy. All patients were given oral contrast, placed prone on a rigid foam cradle with a
depressed area for small bowel exclusion, and instructed to have a full bladder. The CT scans were registered
according to the bones of the pelvis, and the CTV was outlined on each CT slice. Movement of the CTV in all
dimensions was measured. The CT scan with the lowest and highest bladder volume for each patient was used
to calculate the CTV movement due to bladder ﬁlling.
Results: The largest difference in the CTV occurred 10 cm caudal to the anus, with a standard deviation of 1 cm.
Bladder ﬁlling displaced the anterior border of the CTV an average of 7 mm over a cranial to caudal length of
2.5 cm. Other borders of the CTV were based on muscle, bone, or major blood vessels and were stable.
Conclusion: Modiﬁcation of the CTV to design a PTV can be unequal, with the largest change at the anterior
border of the inferior pelvis. © 2002 Elsevier Science Inc.
Rectal cancer, CTV, Organ motion.
INTRODUCTION
One of the primary side effects of adjuvant radiation therapy
(RT) for rectal cancer is acute radiation enteritis (1–6). In a
randomized study of postoperative RT with chemotherapy,
15% to 39% of subjects developed acute Grade 3 diarrhea,
and 11 of the 24 treatment-related deaths were due to
gastrointestinal causes (4). Although the coadministration
of chemotherapy has a great effect on the risk of diarrhea,
the relationship between the volume of small bowel irradi-
ated and the risk of acute radiation enteritis is well known
(7–9). In fact, a recent study using three-dimensional treat-
ment planning tools found that the development of acute
radiation enteritis was highly correlated with the dose and
volume of small bowel irradiation (10). A number of efforts
using surgical and radiation therapy techniques have at-
tempted to reduce this risk by reducing the volume of small
bowel irradiated (11–13).
The rate of diarrhea with postoperative RT has provided
some of the rationale for the administration of preoperative
RT. Studies using the outline of the small bowel on simu-
lation ﬁlms have shown that RT given preoperatively irra-
diated considerably less small bowel than postoperative (7),
suggesting that the surgery led to tethering or ﬁxation of the
small bowel within the posterior pelvis. Multiple single-
institution studies of preoperative RT with chemotherapy
have supported this concept, with considerably lower rates
of diarrhea (14–16). However, randomized trials of preop-
erative RT found acute severe diarrhea in 33–39% of sub-
jects (2, 17, 18), which was probably partly related to the
presence of the primary tumor.
Intensity-modulated radiation therapy (IMRT) is a prom-
ising method for reduction in the volume of small bowel
irradiated. In a preliminary treatment planning study, the
absolute volume of small bowel irradiated to 95% of the
prescription dose was reduced by 11 to 185 cm3 (19).
Although these ﬁndings were very encouraging, before rou-
tine clinical use a number of issues related to internal organ
motion needed to be resolved. This included characteriza-
tion of the position and motion of the small bowel, which is
the primary dose-limiting structure (20).
The target volume can also be variable due to internal
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organ motion. Traditional deﬁnitions of the target volume
may have been anatomically based, but they were always
expressed according to the bones of the pelvis. Therefore, to
study motion of the target volume a formal deﬁnition of the
clinical target volume (CTV) using computed tomography
(CT)-based anatomy was required. This was then compared
on multiple CT scans obtained during treatment. Because
the rectum and bladder can inﬂuence the position of the
CTV, the motion of these structures vs. the position of the
CTV was also measured.
METHODS AND MATERIALS
Ten patients (7 male, 3 female) with rectal cancer had CT
scans of the abdomen and pelvis obtained for planning and
once a week during treatment (55 CT scans total). Six
patients received radiotherapy after a low anterior resection
(LAR), 1 after wide local excision (WLE), and 3 patients
were treated preoperatively (Preop). All patients were given
oral contrast 11⁄2 to 2 h before CT scanning, placed prone on
a rigid foam cradle with a cut-out area for small bowel
exclusion, and instructed to have a full bladder. After align-
ment of the bony pelvis, organs at risk and the CTV were
contoured by the same physician (J.J.N.) and reviewed by
another (J.M.R.). Volumes of the regions of interest were
derived from the Pinnacle 4.2 planning system.
The conventional 3-ﬁeld treatment plan was made by
using the traditional guidelines (4, 11, 21). The superior
border was placed at the middle of the L5 vertebral body.
The inferior border was placed at least 5 cm below the
anastomosis for the LAR patients, and 5 cm below the
tumor or 1 cm below the anus for the Preop and WLE
patients. The posterior border was placed 1.5 to 2 cm
posterior to the anterior border of the sacrum. The anterior
border of the ﬁeld was placed 2 to 3 cm anterior from the
sacral promontory. For the lateral ﬁelds, a femoral block
was designed to block the half of the femur (21).
The CTV was deﬁned as the rectum and perirectal tissues
plus the regional lymphatics (Fig. 1). In the cranial-caudal
dimension, contours of the target structures began at the
inferior edge of L5 and ended at least 4 cm below the
anastomosis for the LAR patients, and 4 cm below the
tumor or below the anus for the Preop and WLE patients.
With corrections for the planning target volume (PTV) and
penumbra, these superior and inferior borders approximated
the conventional ﬁeld. Because the lymphatics follow vas-
cular structures, the distal common and internal iliac arteries
and veins were included plus a 3- to 5-mm margin, depend-
ing on the presence of bowel or bone. The posterior border
of the perirectal tissues was deﬁned by the posterior edge of
the sacral foramina or the most anterior portion of the
gluteus maximus. The lateral border was the ileum, pirifor-
mis, and obturator internus muscles. The anterior border
was deﬁned by the internal iliac vessels, sigmoid colon,
Fig. 1. The shape of the CTV at the superior pelvis (a), upper mid-pelvis (b), lower mid-pelvis (c), and inferior pelvis
(d).
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bladder, vagina, prostate, and small bowel. The small bowel
was always excluded as much as possible; however, if it was
adjacent to the sacrum, then the anterior border of the CTV
was set at least 5 mm ventral to the sacral wall. The colon
of LAR patients was included 2 cm cranial to the anasto-
mosis. In Pre-op patients, the rectum was included 3 cm
cranial to the tumor. The resulting three-dimensional deﬁ-
nition of the CTV had a complex shape with an anteriorly
oriented concavity superior to an inferior cone (Fig. 2).
After registration of the CT scans according to the bones
of the pelvis, the individual contoured CTVs were com-
pared. The variability of the anterior border of the CTV was
obtained by measuring the distance from the midline of the
anterior border of L5/sacrum to the most anterior margin of
each CTV (Fig. 3). Motion of the CTV was calculated for
the individual patient by subtracting the distance of the
anterior margin of the CTV from its mean position on each
CT slice. This allowed calculation of the standard deviation
of all movement. Movement of the rectum in the anterior
and posterior dimension was measured using an identical
method. The positions of the left and right lateral margins of
the rectum were measured from the medial edge of the
bones of the pelvis or the lateral edge of the gluteal muscle
on each slice. This distance was then used to calculate the
rectal motion as was done for the CTV movement. To allow
comparison of the movement of the CTV or rectum between
patients, the CT slice that encompassed the anus was set as
the zero slice. Cranial-caudal motion of the anastomosis was
measured as the movement of the most cranial and most
caudal staples.
To examine the maximal inﬂuence of bladder ﬁlling, the
CT scan with lowest and highest bladder volume of each
patient was reviewed. The anterior to posterior difference in
distance of the two CTVs was measured, as well as the
length of the difference in the cranial-caudal dimension. The
volume difference between the two CTVs was calculated.
Fig. 2. The three-dimensional shape of the CTV (anterior-superior
view).
Fig. 3. Measurement of the anterior border of the CTV. CTV W1  clinical target volume of the ﬁrst CT scan taken
during the ﬁrst week of treatment. CTV W2  clinical target volume of the second CT scan taken during the second
week of treatment.
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RESULTS
The CTV vs. the conventional 3-ﬁeld volume
The femoral block used in the lateral conventional treat-
ment ﬁelds shielded a portion of the CTV at least once in 7
of the 10 individuals. These 7 individuals had a total of 40
scans, of which 16 were found with shielding of the CTV.
In 1 patient, a portion of the CTV was blocked in all of the
scans. In the cranial-caudal dimension, the CTV was
blocked over an average distance of 2.3 cm. In 3 patients,
the CTV was shielded by at least 8 mm in the anterior-
posterior dimension (Fig. 4).
CTV motion
Differences in the CTV appeared to be dependent on the
location within the pelvis. In the superior pelvis, where the
CTV was primarily deﬁned by the common and internal
iliac blood vessels, the anterior border varied according to
the position of the small bowel. Displacement of the anterior
border of the CTV was only observed between the left and
right common or internal iliac vessels. This was related to
the variability of the small bowel, due to the decision to
place the anterior border at least 0.5 cm from sacral wall or
major blood vessels and to include a certain amount of small
bowel if the small bowel was adjacent to these structures. In
the inferior pelvis, the standard deviation (SD) varied from
3 to 10 mm due to the position of the bladder, prostate,
vagina, or rectum. At the anus, the SD of the anterior CTV
position had a value of 3 to 4 mm, which increased to 4 to
6 mm at 5.5 cm above the anus, and to 10 mm 9 cm above
the anus (Fig. 5).
The increase of the SD at 5.5 cm above the anus corre-
sponded with the average position of the bladder ﬂoor,
which was 5.1 cm above the anus, and was caused by the
bladder ﬁlling. The bladder displaced the anterior margin
with an average of 7 mm posteriorly and over an averaged
cranio-caudal length of 2.5 cm. The averaged added volume
associated with an empty bladder was 18 cm3. The highest
CTV volume difference between a full and empty bladder
was 51 cm3. Bladder ﬁlling had no effect on the CTV in 2
patients. They were both female LAR patients.
There was no motion observed of the posterior or lateral
borders. This was expected given the registration according
to the bones of the pelvis and the anticipated stability of the
muscles and major blood vessels.
Rectal motion
The motion of the anterior rectal border was very similar
with the motion of the anterior border of the CTV (Fig. 5).
Thus, it was possible that the rectum may move outside the
anterior margin of the CTV if this border was drawn too
close to the rectum. The lateral margins of the rectum also
Fig. 4. Cumulative percent of patients with maximum distance of blocked CTV (anterior-posterior direction).
Fig. 5. The standard deviation of motion of the anterior border of
the CTV and rectum (1 standard deviation).
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moved to a similar degree; however, because the distance
from rectum to the CTV was much larger in this dimension,
the motion was inconsequential (Fig. 6). The posterior mar-
gin of the rectum was also observed to move, with a SD of
4, 7, and 2 mm at the anus, and 4.5 cm and 9 cm cranial
from the anus, respectively. Motion of the surgical clips
placed at the anastomosis was studied in 5 patients, with the
largest cranial and caudal movements of 1 and 1.5 cm for 4
of the 5 patients, respectively.
DISCUSSION
Traditional treatment planning efforts for rectal cancer
used the bone landmarks of the pelvis and radiopaque soft
tissue markers to design the irradiated volume. With the
development of three-dimensional treatment planning, how-
ever, a much more strict deﬁnition of the CTV was required.
Even though this was more involved, the target volume
deﬁnitions were fundamentally the same, and included the
anastomosis, the mesorectal soft tissues, and the lymphatic
drainage pattern.
The risk of recurrence at the anastomosis has been shown
in multiple studies of the patterns of failure after a low
anterior resection, ﬁnding recurrent disease at the anasto-
mosis in 67% to 80% of all patients with a pelvic recurrence
(22, 23). The mesorectum has also been found to be at risk,
as pathologic examinations of the specimen obtained from a
total mesorectal excision have found an incidence of meso-
rectal tumor deposits in approximately 40% of patients with
a pathologic T3 tumor (24). The designation of the CTV
used in this study included the entire mesorectum with
generous borders, typically extending to the nearest bone or
muscle of the pelvis. The pelvic wall was always included,
as a review of 49 sites of local recurrence in 34 patients
found the pelvic wall to be involved in 24 (25). Perhaps the
most uncertain border of the CTV was along the mobilized
colon immediately proximal to the anastomosis, where we
excluded any large bowel that was more than 2 cm superior
to the surgical clips of the anastomosis. Given the surgical
technique, it was believed to be unlikely that any mesorec-
tum existed anterior to the mobilized colon in this region,
although if any were present then it would have been
excluded from the CTV. Remnants of mesorectum lateral
and posterior to the mobilized colon would have been
included as part of the presacral and vascular volumes in
this region.
The distal border of the CTV was deﬁned based on
studies of the pathologic distribution of disease as well as
reviews of the patterns of failure. Multiple pathologic stud-
ies of the surgical specimens have found no evidence of
cancer more than 4 cm distal to the primary tumor (26–28).
Clinical studies rarely have included the distance of a re-
currence distal to the anastomosis (23, 29), although one
report found that 4 of the 46 recurrences were found 3 cm
distal to the anastomosis (22).
The deﬁnition of the CTV was also determined by the
lymphatic drainage of the rectum (30). Recurrences in
lymph nodes have often been found, with 90% of involved
lymph nodes located in the pelvis (31). The best measure-
ment of lymphatic involvement may be obtained from la-
bor-intensive pathologic studies that use the clearing
method, which has been reported to identify normal lymph
nodes smaller than 4 mm and metastatic lymph nodes that
would not have been identiﬁed using the conventional man-
ual method. With the clearing method, investigators found
an average of over 70 lymph nodes per specimen in 182
patients with rectal cancer. In 70 patients with rectal tumors
below the peritoneal reﬂection, the incidence of any nodal
metastasis was 62.9% for the perirectal lymph nodes, which
included the superior rectal and middle rectal arteries inside
the pelvic plexus, 12.9% for the lymph nodes along the
middle rectal artery outside the pelvic plexus and the inter-
nal iliac artery, and 5.7% for lymph nodes along the com-
mon iliac and obturator arteries (32). Even though the
middle rectal and presacral vessels were not routinely indi-
vidually identiﬁed on the treatment planning CT scan, the
CTV in the inferior pelvis was broadly deﬁned and would
have been expected to always include those structures, as
shown in Fig. 1c. The internal iliac, obturator, presacral, and
distal common iliac vessels were always identiﬁed and were
outlined on the treatment planning CT scan with a margin,
as shown in Figs. 1a and 1b. The presacrum was entirely
included in the CTV.
Although the major blood vessels can be readily identi-
ﬁed on the treatment planning CT scan, there was little
information in the literature to specify the radial distance
from a blood vessel within which unenlarged lymph nodes
lie. Using reports of conventional lymphangiography (33,
34), we decided to place the border of the CTV at least 3 to
5 mm radial to the internal iliac, obturator, and common
iliac vessels, and at least 5 mm anterior to the sacrum. This
speciﬁc issue did not need to be addressed for traditional
treatment planning, but has become much more important
with three-dimensional treatment planning and especially
IMRT, and will need to be resolved for rectal cancer as well
Fig. 6. Lateral and posterior movement of the rectum (1 standard
deviation).
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as any site that involves adjuvant nodal irradiation along
blood vessels.
This study found that the femoral block routinely used in
the lateral ﬁelds of a conventional treatment plan frequently
shielded a portion of the CTV, which was due to internal
organ motion occurring during the course of treatment. This
was not surprising, given that studies of the prostate have
demonstrated that a considerable degree of motion was
possible (35). The shielded area was located at the level of
the bladder, prostate, uterus, vagina, or near the anastomo-
sis. Although the size of the area was relatively small,
approximately 2.5  1 cm, the adjustments applied to the
CTV to form a PTV would have greatly increased the size
of the untreated volume. Irradiation of this particular loca-
tion may be especially important, as the Minnesota reop-
eration series found that nearly one-half of the tumor bed
failures occurred along the posterior prostate and bladder in
men or the rectovaginal septum in women (36). Traditional
simulation methods may be adequate for women, as a ra-
diopaque marker can be placed in the vagina, although there
have been no studies of the effect of rigid marker on the
resting position of the vagina. In addition, before the study
reported here, there has been no examination of the position
of the vagina during the typical 51⁄2-week course of therapy.
In men, delineation of this region would require a Foley
catheter, which is not done routinely. This problem may be
addressed by simply reducing the size of the femoral block
or deleting it entirely. This study, however, suggested that
the best solution was to use three-dimensional treatment
planning, as it provides a much greater degree of conﬁdence
in the anatomic detail, and to add extra margin anteriorly in
this location.
Motion of the CTV was not equal in all dimensions. The
posterior and lateral borders and the anterior border in the
superior pelvis were all very stable, as would be expected
given that these borders were determined by the bone,
muscle, and major blood vessels. The greatest degree of
motion of the CTV was observed near the anterior structures
of the inferior pelvis and was most likely to have been due
to bladder ﬁlling. The rectum also exhibited variability in
position with a SD that was slightly higher than that of the
CTV deﬁnition.
Modiﬁcations to the CTV to account for internal organ
motion when constructing a PTV do not need to be equal in
all dimensions. In all areas other than near the bladder and
prostate or the uterus and vagina, only a minimal increase in
size would be necessary. However, at the anterior border of
the inferior pelvis the modiﬁcation will need to be larger
than the 1 cm SD to ensure coverage of the target volume
during the course of adjuvant treatment in all patients.
Rather than just applying the modiﬁcation as a class solu-
tion, another possible approach would be to obtain multiple
treatment planning CT scans for each patient and individu-
alize the PTV. In fact, studies using this approach, also
known as adaptive radiation therapy, are currently in
progress for prostate cancer (37). Either way, this modiﬁ-
cation would probably have only a minimal effect on the use
of intensity-modulated radiation therapy, as there is no
small bowel in this location.
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Abstract 
Purpose: To investigate the reduction of irradiated small bowel volume with IMRT 
planning in rectal cancer and to asses the variability of the irradiated small bowel in the 
conventional planning as in the IMRT planning by obtaining weekly CT scans.  
Methods and Materials:  Twelve patients with rectal cancer had treatment planning CT 
scans of the pelvis with small bowel contrast obtained for planning and once a week 
during treatment (65 CT scans total).  The scans were registered using the bony structures. 
The clinical target volume, small bowel, large bowel and bladder were outlined on each 
slice.  The first CT scan was used for IMRT planning (IMPlan) and conventional three-
field planning (ConPlan), which were then applied to the CT scans obtained during 
therapy.  
Results:  The median value among patients of the mean volume over a patient’s scan of 
small bowel irradiated ≥95% was 112 cm3 (Standard Deviation (SD): 31 cm3) for the 
ConPlan and 42 cm3 (SD: 17 cm3) for the IMPlan. The median total bladder volume was 
148 cm3 (SD: 130 cm3).  There was a good correlation between the volume of irradiated 
small bowel and the bladder volume for IMPlan with <50 cm3 irradiated small bowel and 
ConPlan with <150 cm3 (p=0.002). 
Conclusion: The use of IMRT led to a potentially clinically meaningful reduction in the 
volume of small bowel irradiated, even when accounting for small bowel motion. A full 
bladder was of greatest benefit in individuals with the smallest volume of small bowel in 
the treatment field. 
 
Résumé 
Objectif: Investigation de la réduction du volume irradié des intestins grêles par 
l'application de la radiothérapie conformationnelle avec modulation d’intensité (RMCI) 
pour le traitement du cancer du rectum, comparée avec le traitement conventionel et 
estimation des variations du volume irradié dans les deux cas. 
Patients et méthodes: Pour douze cas de cancer du rectum, un scan CT du pelvis avec 
contraste intestinal a été fait avant le traitement, ainsi qu'un scan toutes les semaines 
pendant le traitement (65 scans au total). Les scans ont été alignés en utilisant les 
structures osseuses. Le volume cible, les intestins grêles, les gros intestins et la vessie ont 
été délineés dans toutes les coupes. Le premier scan a été utilisé pour faire un plan RMCI 
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et un plan conventiel de trois champs. Ces plans ont été ensuite calculés pour les scans 
obtenus pendant le traitement. 
Résultats: La médiale du volume d'intestins grêles irradiés pour moins que 95% est 112 
cm3 (déviation standard (DS): 31 cm3) pour le plan conventionel et 42 cm3 (DS: 17 cm3) 
pour le plan RMCI. La médiale du volume de la vessie est 148 cm3 (DS: 130 cm3). Il y a 
une bonne corrélation entre le volume de la vessie et le volume d'intestins grêles irradiés 
moins de 50 cm3 pour le plan RMCI en moins de 150 cm3 pour le plan conventionel 
(p=0.002). 
Conclusion: L'utilisation de la RMCI devrait conduire à une réduction substantielle du 
volume d'intestins grêles irradiés, même en tenant compte du mouvement intestinal. Une 
vessie pleine a été grandement bénéfique aux malades avec un petit volume d'intestins 
grêles irradiés. 
 
INTRODUCTION 
Acute diarrhea has been reported to be a frequent side effect of adjuvant 
combined radiation therapy (RT) and chemotherapy for rectal cancer.  Postoperative 
treatment has a reported 20 to 35% rate of grade 3 + diarrhea in randomised trials [18, 26].  
Preoperative RT with chemotherapy has been widely perceived as less toxic, however, 
severe diarrhea rates of 12 to 39% have been reported in randomised studies [15, 24]. 
The relationship between the volume of irradiated small bowel and the 
development of acute small bowel toxicity has been well recognised. In the seventies, 
large parallel opposed fields (APPA) were used [12]. They produced hotspots in areas that 
usually included large and small bowel and played a causative role in the toxicity profile 
of these patients. Exclusion of the small bowel from the pelvis in order to improve the 
tolerance to therapy has been the subject of a considerable number of research efforts.  
The first one was the use of a three- or four-field beam arrangement with an abdominal 
wall compression device (belly board) and bladder distension [10, 12, 16]. An APPA-field 
set up with a patient in supine position resulted in an irradiation of 620 cm3 bowel. In 
contrast, a 4-field technique with a patient in prone position reduced the irradiated bowel 
volume to 145 cm3 [11]. 
Other methods to reduce the amount of small bowel inside the radiation field 
were surgical techniques, such as omental slings, pelvic mesh and tissue expanders [23].  
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Intensity Modulated Radiation Therapy (IMRT) also offers the potential for reducing the 
volume of irradiated small bowel [22].  However, the small bowel is a mobile structure. In 
a study using three-dimensional treatment planning tools, the distance from the sacrum to 
the small bowel at 5 cm caudal to the sacral promontory varied with a standard deviation 
of 2.7 cm, 1.4 cm, and 0.2 cm for preoperative patients, and patients with low anterior 
resections (LAR) and abdominoperineal resections, respectively [20].  The coefficient of 
variation of the volume of small bowel exceeded 100% in the posterior midpelvis for LAR 
and all postoperative patients and in the central midpelvis for preoperative patients 
suggesting that any single study of the small bowel position could be inaccurate in these 
areas.   
Because of the variation in small bowel position and volume observed in the 
previous work, we assessed the variability of small bowel volume for an IMRT plan in 12 
patients who had weekly treatment planning CT scans obtained during routine adjuvant 
pelvic RT.  In order to bring this information into perspective, we used the identical 
methods to assess the variability for a conventional three-field plan. We also investigated 
the role of bladder filling on the volume of irradiated small bowel. 
 
METHODS AND MATERIALS 
Twelve patients with rectal cancer had treatment planning CT scans of the pelvis 
obtained for planning and once a week during treatment (65 CT scans total).  Eleven 
patients had T3 or N+ rectal cancer by transrectal ultrasound or pathologic examination 
and included 2 patients treated after an abdominoperineal resection (APR), 6 after low 
anterior resection (LAR), and treated 3 preoperatively (Preop).  One individual was 
treated adjuvantly after a wide local excision (WLE) for a T2 tumour.  Because this 
person had no intraabdominal surgery, he was included with the preoperative group for 
the purposes of analysis.  There were 4 females and 8 males.  All patients were given oral 
contrast between 1 ½ to 2 hours before the CT scan [7] and placed prone on a vacuum bag 
cradle with a depressed area for small bowel exclusion but rigid foam beneath the pubis 
and the chest.  Patients were instructed to have a full bladder for the simulation and 
reminded of the importance of bladder distension during weekly on-treatment visits. The 
weekly CT scan during treatment was made after the radiotherapy treatment and the 
patients were instructed only to urinate after CT scan was made.   
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There were 4 to 7 CT scans per patient (median of 5) depending on the number 
of weeks that the patient was receiving treatment and patient co-operation.  All CT scans 
were obtained using a helical CT scanner with a 5-mm slice interval and included a 
minimum visualization of the entire treated volume of the pelvis.  The scans were 
registered manually using the bones of the pelvis and the small bowel, large bowel and 
bladder were outlined on each CT slice by a single physician (J.J.N.) and verified by a 
second physician (J.M.R.).   
The first treatment planning CT scan was used to generate two separate treatment 
plans.  One plan used a conventional plan 3-field arrangement with the treatment borders, 
dose and inhomogeneity requirements as per the Southwest Oncology Group guidelines 
for protocol 9304.  This plan placed the superior treatment border at mid-L5, the anterior 
border 3 cm anterior to the sacral promontory, the posterior border was placed 2 cm 
posterior to the anterior border of the sacrum and the inferior border was 1.5 cm inferior 
to the perineal scar in APR patients and at least 5 cm inferior to the anastomosis or tumour 
in LAR and Preop patients, respectively.  The prescription was calculated with the 
isocenter at 100% and a dose inhomogeneity of no more than 105%. 
Each patient also had an IMRT plan calculated, with the clinical target volume 
(CTV) designed to include the rectum, perirectal tissues and regional lymphatics 
according to the standard field definitions and the patterns of failure [12, 21].  In the 
cranial-caudal dimension, contours of the target structures began at the inferior edge of L5 
and ended at least 4 cm below the anastomosis for the LAR patients, and 4 cm below the 
tumour or below the anus for the preop and WLE patients.  With corrections for the 
planning target volume and penumbra, these cranial and caudal borders approximated the 
conventional field.  Because the lymphatics follow vascular structures, the distal common 
and internal iliac arteries and veins were included plus a 3 to 5 mm margin, depending on 
the presence of bowel or bone.  The posterior border of the perirectal tissues was defined 
by the posterior edge of the sacral foramina or the most anterior portion of the gluteus 
maximus.  The lateral border was the ileum, piriformis, and obturator internus muscles.  
The anterior border was defined by the internal iliac vessels, sigmoid colon, bladder, 
vagina, prostate and small bowel.  The small bowel was always excluded as much as 
possible, however, if it was adjacent to the sacrum, then the anterior border of the CTV 
was set at least 5 mm ventral to the sacral wall.  The colon of LAR patients was included 
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2 cm cranial to the anastomosis.  In Pre-op patients, the rectum was included 3 cm cranial 
to the tumour.  The resulting three-dimensional definition of the CTV had a complex 
shape with an anteriorly oriented concavity superior to an inferior cone [21]. 
The planning target volume (PTV) equalled the CTV plus 3 mm margin. The 
IMRT plan consisted of 5 equispaced beams for all patients. The constraints to the PTV 
were set to encompass it within the 95% isodose line while delivering 100% to the 
isocenter, using the Konrad system (MRC, Heidelberg, Germany) for inverse treatment 
planning.  A maximum dose of 110% was allowed as this only occurred within the CTV.  
For the small bowel, a maximum dose of 95% of the prescribed dose or less was allowed 
and the small bowel volume/dose at V(Dk%), with Dk = 40, 60, 80 were minimized. The 
dose distribution of both plans is shown in figure 5.1. Both the conventional and the 
IMRT plan were then applied to the weekly CT images.   
 
Figure 5.1. The dose distribution for the conventional (fig. 1a) and IMRT plan (fig. 1b). 
 
Grey surface: PTV; black line: 100%; grey line: 95%; white line: 80% 
 
Total bladder or total small bowel volumes were derived from the three-
dimensional treatment planning system. The total small bowel volume was equal to the 
amount of small bowel located caudally to the superior edge of L5 and was contoured for 
each patient from the same slice for all of the CT scans.  Small bowel and colon volumes 
inside the 95% or 90% isodose line were derived from the dose volume histograms. To 
compare mean values, the t-test was used.  The patient-specific variation of the irradiated 
bowel volume inside the 95% isodose line was calculated using the standard deviation of 
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the irradiated bowel volume of each patient normalized to the corresponding mean. To 
diminish large variations in the anatomy between the patients, each small bowel volume 
of one patient was divided by the mean volume for that patient with a percentage value as 
result (e.g.: 100 % or 1 equals the mean volume).  The same was done for colon and 
bladder volumes (e.g.: 0.5 results in an almost empty bladder, 1 equals the mean volume 
and 2 results in a full bladder).  These percentage numbers were used in the correlation 
analysis with linear regression.  To view a volume difference over time, all small bowel 
and bladder volumes of every week were summed and averaged from all patients and a 
correlation was calculated. 
 
RESULTS 
Conventional treatment, IMRT and small bowel motion 
The mean small bowel volume within the 95% isodose line for conventional 
treatment was 180 cm3, 160 cm3, and 69 cm3 for APR, LAR and Preop patients, 
respectively (Table 5.1).   
 
Table 5.1. The mean small bowel volume inside the 95% isodose line per patient with 
standard deviation, for conventional treatment and Intensity Modulated Radiation Therapy 
(IMRT) planning. 
Conventional planning IMRT planning 
Small bowel shift 
(SD) 
Small bowel shift 
(SD) 
Surgical 
Procedure Mean small 
bowel volume 
(cc) cc % of mean 
Mean small 
bowel volume 
(cc) cc % of mean 
APR 154 69 45 50 15 30 
APR 206 15 7 69 10 14 
LAR 87 12 14 12 5 42 
LAR 110 15 14 34 17 50 
LAR 247 28 11 81 36 44 
LAR 96 31 34 22 12 55 
LAR 110 60 55 53 45 85 
LAR 308 50 16 120 67 56 
WLE 124 47 38 42 25 59 
Pre-op 34 10 29 3 2 67 
Pre-op 112 50 45 36 22 61 
Pre-op 5 4 80 8 11 137 
SD = standard deviation; APR = abdominoperineal resection; LAR = low anterior 
resection; WLE = wide local excision; Pre-op = preoperative chemoradiation;  
 
The average of the individual standard deviations of the small bowel volume for 
both the postoperative and preoperative groups were similar, with 32 cm3 and 28 cm3, 
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respectively.  With the IMRT treatment plan, the mean volumes were considerably 
smaller than the conventional plan with 59 cm3, 54 cm3 and 22 cm3 for APR, LAR and 
Preop patients, respectively.  This represented a volume reduction of 67%, 69% and 41% 
compared to the conventional plan.  In absolute terms, 11 of the 12 patients experienced a 
reduction in irradiated small bowel volume by a median of 76 cm3 (range 31 to 188 cm3).  
The only patient who failed to benefit had an irradiated mean small bowel volume of only 
5 cm3 with the conventional beam arrangement.  The median standard deviation of 
irradiated small bowel volume was 31 cm3 (range 4 to 69 cm3, mean 33 cm3) for the 
conventional plan compared to a median of 17 cm3 (range 2 to 67 cm3, mean 23 cm3) for 
IMRT.  
 
Figure 5.2.  Distribution of patient-specific variation, percentage relative to the mean, of 
small bowel volume irradiated by at least 95% isodose. 
 
The relative patient-specific variation for small bowel volume irradiated by ≥95% of the 
prescription dose was much larger for IMRT (mean 58%) than for the conventional 
treatment (mean 32%) (Figure 5.2), due to the reduced overall volume irradiated with the 
IMRT plan. For almost all the patients there is 30% higher relative variation of small 
bowel with IMRT than with the conventional plan. 
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Figure 5.3.  Individual bladder volume over time for all patients. 
 
Bladder volume and small bowel volume trends 
The median bladder volume was 148 cm3 (range 29 to 499 cm3).  Despite 
personal instructions at the time of consultation, simulation and weekly during therapy, 
there was a considerable amount of variation observed in absolute bladder volume over 
time (Figure 5.3).  When the bladder volume and the total small bowel volume within the 
pelvis were normalized to the mean, there was a reduction in bladder volume over time, 
while the total small bowel volume was almost constant (Figure 5.4).  There was a trend 
toward an increased volume of irradiated small bowel (14 cm3; p = 0.04) over time for the 
IMRT treatment but a 15 cm3 decrease for the conventional treatment. 
 
Figure 5.4.  The mean bladder and small bowel volume over time. 
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Correlations 
Correlations between the volume of irradiated small bowel inside the 90% 
isodose line and the bladder volume for both the IMRT plan (r = -0.36, p = 0.003) and the 
conventional plan (r = -0.37, p = 0.002) were calculated.  A full bladder reduced the 
volume of irradiated small bowel by 72% for the IMRT plan and by 50% for the 
conventional plan.  The benefit of having a full bladder was greatest for Preop patients, 
with a reduction of 190% (r=-0.61, p=0.001) for the IMRT plan and 130% (r=-0.69, 
p=0.0002) for the conventional plan (Figure 5.5).  There was no correlation for APR 
patients.  
 
Figure 5.5.  Correlation between small bowel and bladder for all patients treated with 
IMRT (fig. 5a) and for preoperatively treated patients with IMRT treatment (fig. 5b). 
 
A good correlation between small bowel and bladder volumes was found for 
IMRT patients with less than 50 cm3 inside the 95% isodose line (r=0.55, p=0.002).  
Patients with > 50 cm3 exhibited no relationship between bladder and small bowel 
volumes (r=0.11, p=0.62) (Figure 5.6).  For the conventional plan, a similar result was 
found if the patients were divided into more or less than 150 cm3 small bowel inside the 
95% isodose line.  In this case, however, bladder distension was associated with a 
reduction in irradiated small bowel by 90% compared to the 150% achieved for the IMRT 
plan in patients with less than 50 cm3 of small bowel. 
No correlation between irradiated small bowel and colon was found, for all 
patients or for any subgroup. 
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Figure 5.6.  Correlation between small bowel and bladder for patients with less (fig. 6a) 
or more than 50 cm3 (fig. 6b) irradiated small bowel with the IMRT treatment. 
 
 
DISCUSSION 
Acute severe bowel toxicity is still a problem as reported by randomised 
chemoradiotherapy trials (Table 5.2) and ranges from 13 to 39% (mean 30%). Late severe 
bowel toxicity is seen in 2 to 30% of the patients, treated with pre- or postoperative 
radiotherapy in randomised trials (Table 5.3).  
 
Table 5.2. Overview of acute severe bowel toxicity in pre-operative randomised 
chemoradiotherapy trials 
 number of 
patients 
RT+ 
SU 
CT+RT
+SU 
SU+RT
+CT 
technique upper field 
border 
dose 
(Gy) 
EORTC 72-76 [6] 245 33 33 x APPA L2 34.5 
NSABP R-03 [15] 116 x 39 23 4-field L5/S1 45 / 50.4 
CAO/ARO/AIO-94
[24] 
805 x 13 12 3- or 4-field L5/S1 50.4 
EORTC 22921 [5] 798 17 34 x 3- or 4-field S2-S3 45 
SU: surgery; RT: radiotherapy; CT: chemotherapy 
 
Although acute and late bowel toxicity is reported by these and many other authors, dose-
volume thresholds have not been reported. Only a few authors reported dose-volume 
correlations by using the outline of the small bowel contrast on orthogonal simulation 
films to calculate the volume of irradiated small bowel. In a study of 150 patients with six 
different primary tumour types, including 51 with rectal cancer, a statistically significant 
association was found between the volume of small bowel in the high dose portion of the 
pelvis and the development of acute diarrhea. The volume of small bowel was on average 
of 116 cm3 for patients with grade 1 diarrhea to 342 cm3 for those with grade 2 diarrhea 
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[11]. In contrast with these results, Shanahan et al. reported a grade 2 diarrhea in 24% of 
the patients with an average irradiated small bowel volume of 102 cm3[25].  
 
Table 5.3: Overview of late severe bowel toxicity in pre- and postoperative randomised 
(chemo)radiotherapy trials 
 Number of 
patients 
Su 
alone 
RT+ 
SU 
SU+ 
RT 
Technique Upper field 
border 
Dose 
(Gy) 
Swedish rectal 
cancer [8] 
1168 10 30 x 3- or 4-field L5 25 
Uppsala [9] 471 6 5 11 3-Field mid L4 25 
Stockholm I [14] 572 7 11 x APPA L2 25 
Stockholm II [14] 455 8 9 x 4-field mid L4 25 
MRC III [1] 469 17 x 20 APPA 18x15 cm 40 
France [3] 172 0 20 x 4-field L4-L5 46 
Rotterdam [27] 172 x x 2 3- or 4-field L5-S1 50 
SU: surgery; RT: radiotherapy 
 
Another study described a grade 2 diarrhea in 31% and 71% of the patients with an 
average irradiated small bowel volume of 23 cm3 and 241 cm3, respectively [13]. The 
addition of chemotherapy complicates the dose-volume correlation even more: Minsky et 
al. reported in his chemoradiotherapy trial a grade 3+ toxicity with an average of 374 cm3 
irradiated small bowel, compared to a grade 0-2 toxicity with an average of 176 cm3 [19]. 
Considering the above mentioned acute dose-volume correlations, the quantification of 
these relationships is not consistent. Possible reasons for this inconstancy are the inclusion 
of non-rectal tumours, different treatment techniques (APPA vs. 3- or 4-field), and the 
inconsistency in small bowel volume measurements due to the method employed, as only 
the outline of the small bowel position was used, not the actual organ volume. 
Only Baglan et al. used treatment planning CT scans in patients treated with pre- or 
postoperative chemoradiotherapy and found grade 3+ acute diarrhea at a dose of 40 Gy 
with an average small bowel volume of 216 cm3, compared to a grade 0-2 toxicity with 78 
cm3. They also reported for grade 3+ toxicity a dose-volume threshold: 125 cm3 small 
bowel at a dose of 40 Gy [4].  
With the conventional treatment, 5 of the 12 patients had 125 cm3 or more irradiated small 
bowel. The IMRT planning for these patients reduced the volume of small bowel 
substantially. However, a reduction of acute bowel toxicity will have to be proven in 
clinical research.The answer to the question if IMRT will result in a reduction of the late 
side effects is even more difficult, because the available data are even more inconsistent: 
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Gallagher et al. reported chronic diarrhea grade 1 and 2 with an average volume of 158 
cm3 and 473 cm3 irradiated small bowel, respectively [11]. Letchert et al. described that 
chronic diarrhea was seen in 31% and 42% of the patients with an average volume of 77 
cm3 and 328 cm3 irradiated small bowel [17]. 
When the effect of the mobility of the small bowel was included in the analysis, 
this study found that IMRT for rectal cancer reduced the mean volume of small bowel 
irradiated to ≥ 95% by approximately one-third of the volume irradiated using a 
conventional three-field arrangement.  In absolute terms, motion of the small bowel had 
approximately the same effect for both IMRT and conventional fields, although the 
relative effect was much higher for IMRT due to the lower total volume of small bowel 
irradiated. 
 In agreement with other studies [11, 12, 20], voluntary bladder distension was 
associated with a smaller volume of irradiated small bowel.  Previous studies, however, 
measured this benefit only once or twice during treatment, using the outline of small 
bowel contrast on simulation films and included very few people with rectal cancer [2, 7].  
In our previous work using three-dimensional treatment planning tools and multiple 
assessment times, a significant relationship was found between the volume of the bladder 
and the height of the small bowel in the cranial-caudal dimension and reduced small 
bowel volume in the anterior mid-pelvis for the LAR and preoperative patients, but not for 
APR patients [20].  There was a trend towards reduced bladder volumes in the last 2 
weeks of treatment, which may have reflected either patient inattentiveness or increased 
difficulty maintaining a full bladder if increased stool frequency was present.   
The dosimetric consequences of bladder distension over the course of treatment 
were examined in this study.  Correlation of the normalized bladder volume to the 
normalized small bowel volume revealed a definite relationship that was strongest for 
patients with less than 50 cm3 and 150 cm3 irradiated small bowel for the IMRT and 
conventional plans, respectively.  Considering that patients with less than 125 cm3 of 
irradiated small bowel had no evidence of acute small bowel toxicity in an analysis using 
three-dimensional treatment planning of conventionally treated subjects [4], it could be 
concluded that voluntary bladder distension was of greatest benefit in those patients who 
needed it the least.  
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CONCLUSION 
With IMRT, the amount of irradiated small bowel was reduced to one third of the small 
bowel volume in the conventional field, but was not beneficial to all patients.  The 
variation of small bowel volume irradiated by ≥ 95% of the prescription dose during 
treatment was on average 32% for the conventional treatment and 58% for the IMRT. 
Despite good instructions, the patients were not able to maintain a full bladder during 
treatment. There was a good correlation between the volume of irradiated small bowel and 
the bladder volume for the IMRT plan with < 50 cm3 irradiated small bowel and the 
conventional plan with < 150 cm3. Further clinical research will have to point out if IMRT 
will result in a reduction of acute bowel toxicity for a selected group of patients.  
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Abstract
HDR intraoperative brachytherapy (IOBT) is applied to locally advanced rectal tumors using a 5 mm thick ﬂexible intraoperative
template (FIT). To reduce the procedure time, treatment planning is performed using standard plans that neglect the curvature of the FIT.
We have calculated the individual treatment plan, based on the real geometry of the FIT, and the dose at clips placed during surgery. A
mean treatment dose of 9.55 ^ 0.21 Gy was found for the individual plan, compared to the prescribed 10 Gy ðP , 0:0001Þ: The mean
central dose was 10.03 ^ 0.10 Gy in the standard plan and 9.20 ^ 0.32 Gy in the individual plan ðP , 0:0001Þ: The mean dose at the
corners of the FIT was 10.3 Gy in the standard plan and ranged between 10.3 and 10.5 Gy in the individual plan. In 63% of the clips, the
dose was larger than 15.0 Gy, which is equivalent to a gap between the FIT and the target smaller than 5 mm. In 18% of the clips, the dose
was smaller than 13.0 Gy indicating that locally the gap was larger than 5 mm. Clinical practice will have to prove if these small
dose deviations inﬂuence the clinical outcome.
q 2004 Elsevier Ireland Ltd. All rights reserved.
Keywords: Brachytherapy; High dose rate; Rectal cancer; Treatment planning
1. Introduction
High dose rate (HDR) intraoperative brachytherapy
(IOBT) is a treatment modality in radiation therapy used
as an adjuvant to surgery for locally advanced cancers [5]. It
involves the delivery of a single large radiation dose to
residual (microscopic) tumor at the time of surgery with a
remotely controlled HDR afterloader. For IOBT, the source
is transported into catheters embedded in a surface
applicator. After tumor resection an appropriately sized
and shaped (custom-made) applicator is placed on the
residual (microscopic) tumor and secured into place.
Adjacent organs can be either shielded or retracted away
from the treatment area. The irradiation time is determined
either through individual planning after simulation of the
IOBT geometry [15] or using preplanned atlases [3,13].
In 1994 an Integrated Brachytherapy Unit (IBU)
(Nucletron, The Netherlands), i.e. a shielded operating
room equipped with an HDR afterloader (microSelectron
HDR, Nucletron, The Netherlands) and a dedicated
brachytherapy localizer (Nucletron, The Netherlands), was
established at the Erasmus MC-Daniel den Hoed Cancer
Center [8]. This set-up enables integration of the entire
brachytherapy procedure, i.e. implantation, implant recon-
struction, dose planning and irradiation in a single session.
The IBU is an ideal and economic environment both for
(fractionated) HDR brachytherapy [9,10] as well as for
IOBT.
In our institution, IOBT is used as part of a multimodality
treatment for locally advanced primary or recurrent rectal
tumors since 1997 using a ﬂexible intraoperative template
(FIT). To reduce the total procedure time, treatment
planning during IOBT is performed using standard geome-
tries, i.e. ﬂat templates neglecting the curvature of the FIT,
present in the treatment planning system. For each patient
an individual treatment plan is calculated after ﬁnishing the
procedure. The individual treatment plan is based on
reconstruction of the FIT geometry and clip locations* Corresponding author.
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from isocentric ﬁlms and importing the actual dwell times.
The purpose of this paper is to discuss the feasibility of our
technique for IOBT of rectal tumors. The question is raised
whether the dose reduction towards the treated area, caused
by the curvature of the FIT, can be neglected. For this
reason, the individual treatment plans and the standard plans
were compared in terms of dose at the prescribed depth from
the surface of the FIT. IOBT applicators are always
presented as blankets enclosing every irregularity. How-
ever, with catheters in place, the ﬂexibility of the applicator
is reduced and small irregularities are not covered. Even
after pressing gauze dressings into the pelvis, the applicator
could reshape, and a gap between the applicator and the
target surface can occur. The only way to deﬁne the dose at
the surface retrospectively was to determine the dose at the
clips, enabling calculation of the gap between the FIT and
the target surface at the clip areas.
2. Materials and methods
IOBT is applied to locally advanced primary or recurrent
rectal tumors using a FIT. The FIT is a 5 mm thick ﬂexible
silicon template containing parallel catheters spaced 1 cm
apart (Fig. 1). The shape of the FIT can be rectangular or
corners can be cut off to conform to the target area. During
surgery the size and shape of the FIT are determined by the
surgeon and radiation oncologist. The shape, in combination
with the catheter positions, is overlaid on a paper template
which is used as input for the treatment planning system
(Plato BPS, Nucletron, The Netherlands). Treatment plan-
ning is performed using standard geometries, i.e. ﬂat
templates neglecting the curvature of the FIT, present in
the treatment planning system. Active dwell positions are
chosen according to the size and shape of the actual FIT as
present on the paper template. The dose is speciﬁed at the
reference depth (usually 10 mm from the surface of the FIT,
which is equal to 12.5 mm from the center of the catheters).
For each active dwell position, a dose point is placed on
a line perpendicular to the FIT at the reference depth.
The dwell times are optimized such that the dose in the dose
points is as homogeneous as possible using the ‘optimiz-
ation on dose points on distance’ algorithm as implemented
in Plato BPS (Nucletron, The Netherlands) [16]. The
reference dose is deﬁned as the average dose in the dose
points and is in the case of rectal cancer 10.0 Gy. The
procedure with standard plans is chosen to eliminate
the time-consuming catheter reconstruction. Before the
irradiation is started, the irradiation time is checked by an
independent manual calculation [14]. During treatment
planning, isocentric reconstruction ﬁlms are made using the
dedicated brachytherapy localizer [8]. Reconstruction of the
actual FIT geometry, using these ﬁlms, is performed after
the IOBT procedure is ﬁnished. The individual treatment
plan is calculated by importing the dwell times from the
standard treatment plan in the reconstructed FIT geometry.
The actually delivered dose, i.e. the treatment dose, is
deﬁned as the average dose in dose points, placed on a line
perpendicular to the reconstructed FIT at the prescribed
depth. This dose is expected to be less than 10.0 Gy due to
the anatomy of the pelvis.
For evaluation of the procedure, the treatment dose, as
calculated in the individual plan, was compared to the
prescribed dose of 10.0 Gy. Also, a comparison of the dose
in a selection of ﬁve dose points, located at the prescribed
depth in both the standard plan and the individual plan, was
made. One dose point was chosen centrally in the target area
and four on each corner, i.e. located at the outermost
catheters at the third dwell position (10 mm from the edge)
(Fig. 2).
Fig. 1. The ﬂexible intraoperative template (FIT); indicated are the catheter
spacing of 1 cm and the FIT thickness of 0.5 cm.
Fig. 2. Example of a (ﬂat) FIT geometry (a rectangle with two corners cut
off), consisting of seven catheters spaced 1 cm apart with active dwell
positions spaced 5 mm apart. p , the position of the ﬁve dose points (D1,
D2, D3, D4, D5) used for evaluation.
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During surgery, clips were placed at the tissue surface to
delineate the target area. The position of the clips was
reconstructed from the reconstruction ﬁlms. The calculated
dose in the clip locations in the individual treatment plan is
representative for the local dose at the target surface and
was used as a measure of the gap between the FIT surface
and the target. This way the depth in tissue covered by the
reference dose can be determined. A FIT containing seven
catheters of 6 cm each was considered. The central plane of
this FIT, i.e. the plane perpendicular to the catheters and
located at the center of the catheters (y ¼ 0 mm), is drawn in
Fig. 3A. Three trajectories are indicated, i.e. at the center of
the FIT (x ¼ 0 mm), in between catheters 5 and 6
(x ¼ 15 mm) and at the edge of the FIT (x ¼ 30 mm). For
each of these trajectories a depth dose curve, i.e. the dose
along the z-axis, is printed in Fig. 3B. A fourth trajectory is
calculated at x ¼ 0 mm and y ¼ 25 mm (5 mm from the
edge of the FIT, i.e. through the second dwell position in
catheter 4). The dose is plotted as a function of the distance
from the centers of the catheters which are located at
z ¼ 0 mm. The distance between the clips (located at the
tissue surface) and the center of the catheters would be
2.5 mm in case of a perfect ﬁt between the FIT and the
target. This corresponds with a dose ranging between 17.5
and 42.5 Gy, strongly depending on the location along the
FIT (Fig. 3B). In case of a 5 mm gap between the FIT and
the target, the clips would be at 7.5 mm from the center of
the catheters. The dose at the clip locations will then vary
between 13.0 and 15.0 Gy. In the latter case, the actually
delivered dose will be located at 5 mm depth in tissue as the
dose was prescribed at 10 mm from the FIT surface.
3. Results and discussion
Thirty-nine patients were included in the analysis. The
number of catheters used was on average 8.4 (range 5–14),
corresponding to an average of 146.3 dwell positions (range
49–341). The number of clips placed in each patient varied
between 0 and 7, mean 3.5. The reference depth was 10 mm
from the FIT surface in 37 cases. In two cases a combination
of two reference depths, i.e. 5 mm and 10 mm, was used.
The average air kerma strength of the HDR source was
29 300 cGy h21 cm2 (range 16 000–46 300 cGy h21 cm2)
resulting in an average irradiation time of 26 min 28 s
(range 9 min 5 s–66 min 2 s). When recalculating the
irradiation time using a newly installed HDR source (with
a source strength of approximately 40 840 cGy h21 cm2) an
average irradiation time of 17 min 8 s (range 8 min 42 s–
32 min 14 s) was found depending on the size of the FIT.
Fig. 3. (A) A plane through the center (y ¼ 0 mm) of a FIT containing seven catheters of 6 cm each, with the 200, 150, 125, 100 and 50% isodose lines shown.
(B) The depth dose curves along the z-axis for the FIT geometry shown in (A).
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When looking at the total procedure time, other factors have
to be taken into account too, e.g. preparation of the radiation
oncologist, adjustment and positioning of the FIT, treatment
planning, preparation for the irradiation, check cable run
and removal of the FIT. In literature, wide ranges are found
for total irradiation times and procedure times in similar
IOBT studies [4,13]. We estimate that the time needed for
treatment planning could be reduced by about 45 min when
using standard plans.
In four patients, the standard plan was only available
because it was not possible to make (isocentric) reconstruc-
tion ﬁlms. For two patients the standard plan was not
available as the individual treatment plan was calculated
during the application. One patient was excluded from the
evaluation because he was treated at two separate sites using
a single standard plan. Therefore, the standard plan could be
compared to the individual plan in 32 patients. An average
treatment dose of 9.55 ^ 0.21 Gy was found for the
individual treatment plan while the reference dose in the
corresponding standard plan was always 10.0 Gy ðP ,
0:0001Þ: The dose in the individual plan was lower than in
the standard plan due to the curvature of the FIT and
because the dose was prescribed at the convex side of the
FIT. The average central dose, i.e. the dose in dose point D3,
was 10.03 ^ 0.10 Gy in the standard plan and
9.20 ^ 0.32 Gy in the individual plan ðP , 0:0001Þ: In
the standard plan, the average dose in the dose points at the
corners of the FIT, i.e. D1, D2, D4 and D5, was 10.3 Gy
(Fig. 4). The variation of the dose in these points was small
as a result of the dwell time optimization. In the individual
plan the average dose in these points varied between 10.3
and 10.5 Gy (Fig. 4). In other studies using preplanned
dosimetry atlases [1–4,6,11–13], no information is pro-
vided on the actual dose delivered at the reference depth.
This dose will deviate from the prescribed dose due to the
curvature of the applicator. Harrison et al. [3] have
investigated the effect of applicator curvature in order to
make an extensive atlas of both planar and moderately
curved applicators. Kneschaurek et al. [7] also investigated
this effect. However, they use equal dwell times and
prescribe the dose in the center of the target at the applicator
surface. Clinically they do not account for the applicator
curvature as the effect is negligible when prescribing at the
applicator surface.
On a total of 134 clips implanted, 113 clips were located
perpendicular under the FIT. In 20 clips (18%) a dose lower
than 13.0 Gy was found, indicating a gap of 5 mm or more
between these clips and the FIT surface (Fig. 3). Therefore,
the reference dose was located at less than 5 mm depth in
tissue. For 71 out of 113 clips, the calculated dose was larger
than 15.0 Gy which is equivalent to a gap smaller than
5 mm, meaning that locally a dose of 10.0 Gy was delivered
to at least 5 mm depth in tissue (Fig. 3). In 22 clips (19%) a
dose between 13.0 and 15.0 Gy was calculated. In this case
the conclusion on gaps depends on the location of the clip
along the FIT (Fig. 3). Unfortunately this evaluation does
not give us the dose in the center of the target, i.e. the area
most at risk, because the clips were positioned at the edge of
the close or positive resection margins. Therefore, we
recommend that extra clips should be placed in the center of
the target. In that case the same evaluation method could
give information on the gap between the target and the FIT
surface and thus the depth of the treatment isodose in tissue
right in the area most at risk. In general in IOBT literature,
information is given on a prescribed dose and a reference
depth as a distance from the surface of the applicator [1–4,
6,11–13]. However, the gap between the applicator and the
tissue surface determines the actual reference depth in
tissue. Due to the curvature of the target area it is not
realistic to assume that this gap will always be negligible.
The actual dose in tissue should be presented, e.g. by
analysing the dose in clips placed centrally at the target
surface. Clinical practice will have to prove if the small dose
deviations caused by neglecting the FIT curvature in the
standard plans and by potential gaps between the FIT and
the target inﬂuence the clinical outcome.
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HIGH-DOSE-RATE INTRAOPERATIVE RADIOTHERAPY FOR CLOSE OR
POSITIVE MARGINS IN PATIENTS WITH LOCALLY ADVANCED OR
RECURRENT RECTAL CANCER
JOOST J. NUYTTENS, M.D.,* INGER-KARINE K. KOLKMAN-DEURLOO, M.SC.,*
MAARTEN VERMAAS, M.D.,† FLORIS T. FERENSCHILD, M.D.,† WILFRIED J. GRAVELAND, M.SC.,‡
JOHANNES H. DE WILT, M.D., PH.D.,† PATRICK E. HANSSENS, M.D.,* AND
PETER C. LEVENDAG, M.D., PH.D.*
Departments of *Radiation Oncology, †Surgical Oncology, and ‡Statistics, Erasmus Medical Center, Daniel Den Hoed, Rotterdam,
The Netherlands
Purpose: A high-dose-rate intraoperative radiotherapy (HDR-IORT) technique for rectum cancer was developed
and the technique, local failure, and survival were analyzed.
Methods and Materials: After the exclusion of metastatic patients, 37 patients were treated with external beam
RT, surgery, and HDR-IORT between 1997 and 2000. Primary locally advanced rectum cancer was found in 18
patients and recurrent disease in 19. HDR-IORT was only administered if the resection margins were <2 mm.
The ﬂexible intraoperative template is a 5-mm-thick pad with 1-cm-spaced parallel catheters. Clips were placed
during surgery to deﬁne the target area. A dose of 10 Gy was prescribed at a 1 cm depth from the template
surface and calculated using standard plans. After treatment, the dose at the clips was calculated using the
reconstructed template geometry and the actual treatment dwell times. The median follow-up of surviving
patients was 3 years. No patients were lost to follow-up.
Results: Overall, 12 patients (32%) had local recurrence, 5 (14%) of which were in the HDR-IORT ﬁeld. The
3-year local failure rate for primary tumors and recurrent tumors was 19% and 52%, respectively (p  0.0042).
The 3-year local failure rate was 37% for negative margins and 26% for positive margins (p 0.51). A high mean
dose at the clip (17.3 Gy) was found. The overall survival was signiﬁcantly different for primary vs. recurrent
tumors, stage, and grade.
Conclusion: Because of the HDR technique, a high dose at the clips was found, with good local control. More
out-of-ﬁeld than in-ﬁeld failures were seen. The local failure rate was signiﬁcantly different for primary vs.
recurrent disease. © 2004 Elsevier Inc.
Rectal cancer, Intraoperative radiotherapy, Brachytherapy, Local recurrence.
INTRODUCTION
Primary locally advanced and recurrent rectum tumors are a
heterogeneous group of tumors, that include intrapelvic
tethered rectum tumors, ﬁxed tumors, enlarged nodes, and
metastatic disease.
The risk of developing local recurrence after treatment of
a primary tumor increases with increased stage. Treatment
of early-stage rectal cancer with preoperative radiotherapy
(RT) and total mesorectal excision resulted in a recurrence-
free rate of 94% for Stage II and 85% for Stage III tumors
(1). More advanced rectal tumors treated with postoperative
RT and chemotherapy resulted in a recurrence-free rate of
73% for low-risk patients (T1–T2N or T3N0) and 48% for
high-risk patients (T3N or T4, any N) (2).
Survival after recurrence depends on stage and treatment
and this results in a 3-year survival rate varying from 0% to
60% (3–5). The cause of death in these patients is often
systemic disease. However, a mortality rate of 16–44%
owing to local failure has been reported (6, 7). Fixed or
tethered rectum tumors often invade the adjacent organs or
pelvic wall and result in an even worse local control and
survival. To treat these latter tumors, intraoperative RT
(IORT) was developed, because the conventional doses and
techniques were insufﬁcient or would lead to a greater
incidence of radiation complications.
Two techniques have been in use: intraoperative electron
beam radiotherapy (IOERT) and high-dose-rate brachyther-
apy (HDR-IORT). The advantages of IOERT are the treat-
ment depth to 1 cm with a choice of electron energies and
quick delivery of the radiation (10 min). The ﬂexible
template in HDR brachytherapy can treat all surfaces; how-
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ever, the treatment times and total procedure times are
longer. The steep dose gradient between the target surface
and the reference depth is another advantage, because the
highest dose is at the area at risk. However, it also limits the
use of intraoperative brachytherapy to target depths 0.5–1
cm. Because of these differences, the treatment indications
can be different and the results of these two techniques are
not completely comparable. IOERT is the most frequently
used technique. At least 14 cancer centers (5, 7–19) have
reported their results with IOERT, and only 3 have reported
their results with HDR-IORT (4, 20, 21).
These three cancer centers used a 1-cm-thick pad as a
template and often prescribed a dose of 15 Gy at the surface
or at 0.5 cm depth from the pad. We changed this technique
to create a high dose at the surface and a steep dose gradient.
We developed a 0.5-cm-thick pad and prescribed a dose of
10 Gy at 1 cm depth from the pad surface. In 1997, the
HDR-IORT program was started at the Erasmus Medical
Center–Daniel Den Hoed Cancer Center. The HDR-IORT
was only performed if the resection margins on frozen
section analysis were 2 mm. Thirty-nine patients with
locally advanced primary or locally recurrent rectum cancer
had close or positive margins on frozen section analysis and
were treated during surgery with HDR-IORT. All patients
received preoperative external beam RT (EBRT) to the
tumor and pelvis. To evaluate our alternative HDR-IORT
technique, an analysis of the local failures was made with
regard to the location of the local recurrence.
METHODS AND MATERIALS
EBRT and surgery
Between 1997 and 2000, 97 patients with locally ad-
vanced primary or recurrent rectum tumors were treated
with EBRT. After preoperative screening (CT scan of tho-
rax, abdomen, and pelvis), 23 patients were not eligible for
surgery because of poor performance status, inoperable
tumors, or distant metastases. Of the 74 patients, 39 had
close or positive resection margins and were treated with
HDR-IORT. During resection, 2 patients were diagnosed
with metastasis and were excluded from this analysis. Of the
remaining 37 patients, 18 had primary locally advanced
rectum cancer and 19 had recurrence. All patients had
adenocarcinoma. The patient characteristics are shown in
Table 1. Five patients received 25 Gy preoperative EBRT in
ﬁve fractions and 31 patients received 50 Gy in 25 fractions.
One patient with recurrent cancer was previously treated
with 50.4 Gy and received for the second RT session an
EBRT dose of 30.6 Gy in 1.8-Gy fractions. EBRT was
delivered by either a three-ﬁeld technique, using one pos-
terior and two lateral portals or a four-ﬁeld box technique.
The pelvic ﬁeld borders were deﬁned as follows: the lateral
borders extended 1.5 cm lateral of the bony pelvis, with the
cranial border the promontory (L5-S1), and the caudal bor-
der was at least below the foramina obturatoria to 2 cm
under the anus, depending on the tumor position. The dorsal
border encompassed the sacrum, and the anterior border was
chosen in such a way that the tumor region was widely
covered. None of the patients received pre- or postoperative
chemotherapy. Some patients were treated with chemother-
apy, if metastases were diagnosed during follow-up. For
each patient, the selected type of surgery was based on the
ﬁxation and location of the tumor. One low anterior resec-
tion, 21 abdominoperineal, and 15 abdominosacral resec-
tions were performed. Forty organs or adjacent structures
were completely or partially resected (Table 2). The median
follow-up of the surviving patients was 2.8 years for the
patients with primary tumors and 3.3 years for those with
recurrence. No patients were lost to follow-up.
Intraoperative RT
The ﬂexible intraoperative template (FIT) developed at our
department is a 5-mm-thick pad made of ﬂexible silicon with
Table 1. Patient characteristics
Total Primary Recurrent
Patients (n) 37 18 (49) 19 (51)
Median follow-up of surviving
patients (y) 3.0 2.8 3.3
Stage (n)
T3N0 20 (54) 12 (66) 8 (42)
T4N0 12 (32) 3 (16) 9 (47)
T1-4N1 5 (14) 3 (16) 2 (11)
Margin (n)
Negative 19 (51) 11 (61) 8 (42)
Positive 18 (49) 7 (39) 11 (58)
Gender (n)
Male 25 (70) 12 (66) 13 (74)
Female 12 (30) 6 (34) 6 (26)
Differentiation grade (n)
1 3 (8) 3 (17) 0 (0)
2 29 (78) 14 (78) 15 (79)
3 4 (11) 0 (0) 4 (21)
Unknown 1 (3) 1 (6) 0 (0)
Resection (n)
LAR 1 (3) 0 (0) 1 (5)
APR 21 (57) 15 (83) 6 (31)
ASR 15 (40) 3 (17) 12 (63)
Age (y)
0–49 9 (24) 6 (33) 3 (16)
50–69 18 (49) 8 (44) 10 (53)
70–79 10 (27) 4 (22) 6 (31)
Abbreviations: LAR lower anterior resection; APR abdom-
inoperineal resection; ASR  abdominosacral resection.
Numbers in parentheses are percentages.
Table 2. Resection of organs
Resection No (n) Yes (n) Partially (n)
Bladder 28 7 2
Prostate 13 7 5
Posterior vaginal wall 5 7 0
Uterus with adnex 8 4 0
Small bowel 33 0 4
Sacrum 22 0 15
Psoas 33 0 4
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1-cm-spaced parallel source guide tubes running through the
center of the template. Before positioning the FIT, three to four
surgical clips were placed generously around the target surface.
The size and shape of the FIT were then adjusted to the target
surface. The FIT, in combination with the catheter positions,
was overlaid on a paper template. The paper template was used
as input for the treatment planning system (Plato BPS, versions
13.3 and 13.7, Nucletron, The Netherlands). After positioning,
the FIT was pressed against the area at risk by ﬁlling the pelvis
with gauze pads. This was done to avoid the bolus effect from
blood and/or surgical ﬂuid during IORT and to push critical
organs away from the FIT. Two orthogonal radiographs were
taken to see whether the target surface (clips) was encom-
passed by the applicator. Treatment planning was performed
using the standard geometries present in the treatment planning
system. A dose of 10 Gy was delivered, usually at 1 cm depth
from the applicator surface. The prescription depth was altered
to a combination of 0.5 and 1 cm for 1 patient and for another
patient to 1 and 2 cm. After treatment, the dose at the clips was
calculated using the reconstructed template geometry and the
actual treatment times. IORT was only administered if resec-
tion margins to the tumor were2 mm, which was judged on
frozen section analysis. In the ﬁnal pathology report, positive
margins were found in 18 patients and negative margins in 19
patients. Of these 19 patients, 4 had a resection margin 1
mm. Profuse bleeding or hemodynamic instability during sur-
gery occurred in 7 patients. For these 7 patients, clips were not
placed and/or orthogonal radiographs were not taken to reduce
the operation time. In total, 129 clips were placed; 112 clips
were apparently positioned directly under the FIT and 17 just
at the edge of the FIT. The posterior and/or right pelvic walls
were most frequently treated with the FIT (Table 3). On
average, 8 tubes with a FIT surface of 69 cm3 were used. The
mean radiation time was 27 min (Table 4).
Deﬁnitions and statistical analysis
A local recurrence was deﬁned as tumor regrowth within
the EBRT ﬁeld, and an IORT in-ﬁeld recurrence was de-
ﬁned as a recurrence completely or partially within the
IORT ﬁeld, as seen on CT or MRI. Local recurrence and
distant metastasis were scored until patient death and cen-
sored thereafter. Local control and survival curves were
calculated using the actuarial Kaplan-Meier method. Com-
parisons for survival were made using the log–rank test. For
other comparisons, the Kruskal-Wallis test was used.
RESULTS
Local control
Twelve patients (33%) developed local recurrence, ﬁve re-
currences were in the IORT ﬁeld and seven were out-of-ﬁeld.
One IORT in-ﬁeld failure (1 of 18 patients; 6%) was seen in
the primary locally advanced group and four (4 of 19 patients;
21%) in the recurrence group. Three IORT in-ﬁeld failures
were diagnosed in patients with positive resection margins.
The median time to local recurrence was 4.5 years (Fig. 1). The
3-year actuarial failure rate for primary and recurrent tumors
was 19% and 52%, respectively (p  0.042, Fig. 2a). For
patients with an abdominoperineal resection, the mean time to
local failure was 4.2 years; for those with an abdominosacral
resection, it was 2.8 years (p  0.043, Fig. 2b). The 3-year
local failure rate was 37% for those with negative margins and
26% for those with positive margins (p  0.51, Fig. 2c).
Table 3. Place of FIT in the pelvis
Place of FIT n
Posterior pelvic wall 1
Posterior and left lateral pelvic wall 8
Posterior and right lateral pelvic wall 9
Posterior, left and right lateral pelvic wall 2
Posterior, left and right lateral, and anterior
pelvic wall 0
Anterior pelvic wall 6
Anterior and left lateral pelvic wall 0
Anterior and right lateral pelvic wall 1
Anterior, left and right pelvic wall 4
Left lateral pelvic wall 2
Right lateral pelvic wall 4
Abbreviation: FIT  ﬂexible intraoperative template.
Table 4. IORT characteristics
Characteristic
Median
(range) Mean SD
Catheters (n) 7 (5–14) 8 2.7
FIT surface (cm2) 60 (24–161) 69 35
Radiation time (min) 21 (10–66) 27 14
Clips (n) 4 (2–7) 4 1.1
Abbreviations: IORT  intraoperative radiotherapy; FIT 
ﬂexible intraoperative template.
Fig. 1. Overall time to local recurrence.
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Out-of-ﬁeld failures were seen earlier than in-ﬁeld failures
(median time 16 vs. 31 months, p  0.077).
Eight of the 12 local failures were located in the posterior
pelvis (Fig. 3). The median distance of the out-of-ﬁeld
recurrence to the area treated with the FIT was 2 cm (range
1–5). Four recurrences were found growing in the sacrum or
sacral foramina.
IORT technique
The mean dose to all clips was 15.79 Gy. The mean dose
to the 112 clips under the FIT and 17 clips at the edge was
17.27 and 6.05 Gy, respectively. Of the 112 clips, 20
received a dose 13 Gy. A dose 10 Gy was calculated in
4 of these 20. Patients with and without an in-ﬁeld recur-
rence had a mean clip dose of 18.00 Gy (range 12.39–
24.42) and 17.21 Gy (range 7.15–42.64). Patients with an
in-ﬁeld recurrence had a mean FIT of 82 cm2 compared
with 67 cm2 for the rest of the patients (p  0.63). No
relationship between the size of the FIT, number of resected
organs, or topography of local recurrences was found.
Complications
At the start of EBRT, 57% of the patients complained of
pain, 32% of irregular stools, 27% of intrapelvic discomfort,
and 5% of urinary problems. Postoperatively, many com-
plications were diagnosed, including a delay in wound heal-
ing in 46%, abscesses in 16%, leakage at the anastomosis
site in 5%, and ﬁstulas in 8%. Plexopathy was found in 14%
of the patients. Only 3 patients had late complications: one
had chronic diarrhea (Radiation Therapy Oncology Group
[RTOG] Grade 1), another had chronic pain in the pelvis
(RTOG Grade 2), and the last had radiating pain to the
lower extremities (RTOG Grade 2). Sacral necrosis was not
found.
Overall survival
The actuarial 5-year survival rate was 38%, with a me-
dian survival of 2.8 years (Fig. 4). The 3-year overall
survival rate for patients with primary and recurrent tumors
was 61% and 34%, respectively (Fig. 5a), and this differ-
ence was statistically signiﬁcant (p  0.016). Two patients
Fig. 2. Time to local recurrence for (a) primary/recurrent tumor, (b) resection type, and (c) resection margin. APR 
abdominoperineal resection; ASR  abdominosacral resection.
Fig. 3. Place (centrum) of recurrence after IORT. Triangles indicate out-of-ﬁeld IORT recurrence; squares indicate
in-ﬁeld IORT recurrence.
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(5%) died of local disease and 17 (46%) of metastases. Of
these 17 patients, 4 died of peritonitis carcinomatosa. Sev-
enteen patients were still alive, 13 without disease, at last
follow-up. The overall survival was signiﬁcantly different
according to stage (p  0.0016) and grade (p  0.0012;
(Fig. 5b,c). Patients 50 years had a median survival of 2.2
years compared with 4.4 years for patients 50 (p  0.31).
Distant metastases were found in 18 patients. Several
patients had metastasis in 1 organ: 5 patients had metas-
tasis in the liver, 8 in the lung, 4 in the peritoneum, and 7 in
other locations. No patients with liver metastasis were res-
cued by surgery. Metastases were found in 44% and 53% of
the patients with primary and recurrent tumors, respectively.
The metastasis-free survival was not signiﬁcantly different
between primary and recurrent tumors (p  0.45).
DISCUSSION
The use of IORT for rectal cancer has been reported by at
least 17 cancer centers; however, only 3 of these 17 used
HDR-IORT. Two centers (4, 22) used a 1-cm-thick pad
(HAM applicator) and usually prescribed a dose of 15 Gy at
0.5 cm from the pad surface. The third center also devel-
oped a 1-cm-thick pad, but prescribed a dose of 15 Gy to the
surface (23). Our technique is different, with the use of a
0.5-cm-thick pad and a prescribed dose of 10 Gy to 1 cm
from the pad surface. The advantages of this thinner pad are
the increased ﬂexibility and higher surface dose. In combi-
nation with dwell time optimization, doses up to 40 Gy to
the clips were found at the corners of the template, as
veriﬁed by the clip doses. According to the dosimetric
characteristics of our technique, a clip dose of 13 Gy
indicated a gap between the FIT and area of risk of 5 mm
or a well-positioned template at the clip. An adequate dose
at the clip was found in 82%. Although the thinner template
is more ﬂexible, we still found a gap of5 mm between the
FIT surface and the clips in 18%. However, we only found
a dose 10 Gy in 3.5% of the clips, so we may assume that
our technique was well carried out. The cause of the in-ﬁeld
failures was not found. No dose difference in patients with
and without in-ﬁeld failures was found.
Although high doses were applied to the surface, only 3
patients complained of late toxicity. Two patients reported
chronic radiating pain and one chronic diarrhea. The post-
operative toxicity of the integral treatment was high, as
reported by many authors (4, 7, 10, 20, 24, 25). Many
patients underwent extended resection combined with pre-
operative RT. It was often difﬁcult to assign a particular
complication as being a result of surgery or RT. Huber et al.
(21) found a signiﬁcant greater complication rate in patients
treated with HDR-IORT, Hashiguchi et al. (7) described a
trend, and Noyes et al. (26) found no difference in their
combined analysis of 220 patients.
Five of the 12 local recurrences were IORT in-ﬁeld
recurrences. Because more out-of-ﬁeld failures were found
than in-ﬁeld failures, it can be assumed that IORT is an
effective treatment. However, a randomized trial is needed
to conﬁrm this. Nine studies (7, 8, 10, 11, 19–21, 24) also
reported the site of recurrence. For primary tumors and
recurrent tumors, 17% and 49% of the local failures were in
Fig. 4. Overall survival.
Fig. 5. Survival according to (a) primary/recurrent tumor, (b) stage, and (c) grade.
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ﬁeld, respectively (Table 5). Because out-of-ﬁeld failures
were more frequent than in-ﬁeld failures, the question is
raised of how the occurrence of these out-of-ﬁeld failures
can be reduced. Our out-of-ﬁeld failures were within 5 cm
of the IORT area and could be included by extending the
FIT. However, four local failures were located in the sacrum
or sacral foramina. HDR-IORT probably could not have
prevented these local failures, because they were situated
close to the nerves. The question arises whether higher
doses or larger FITs could have prevented the other recur-
rences, without increasing the toxicity.
As opposed to other reports, we did not ﬁnd that close or
positive margins resulted in differences in the local recurrence
rate (p  0.51). Many authors (4, 8, 11, 14, 22, 27) have
reported a statistically signiﬁcant difference in the local failure
rate according to the resection margin. However, they usually
compared negative margins with microscopically positive mar-
gins or gross total resection margins and not close margins (2
mm) with positive margins. Extended resections, such as ab-
dominosacral resections and total and partial organ resections,
were often performed. Patients who underwent abdominosa-
cral resection had a signiﬁcantly different greater local failure
rate than did patients with abdominoperineal resection (p 
0.043). This can be explained by the larger amount of disease
or more aggressive character of the tumor when abdominosa-
cral resections were necessary.
Of our patients, 33% had local failure. For primary lo-
cally advanced tumors, the 3-year local failure rate was
19%. Other authors found a comparable 3-year local failure
rate of 16% and 23% (1, 2). Harrison et al. (27) reported a
2-year local failure rate of 19%. Recurrent tumors had a
3-year local failure rate of 52%. The reported 3-year local
failure rate varies between 53% and 79% (4, 6, 8, 19, 22).
A statistically signiﬁcant difference (p  0.042) in the time
to local failure between the primary and recurrent tumors
was found, but has not been previously reported.
Patients with primary tumors survived longer than pa-
tients with recurrence (p  0.016). The 2-, 3-, and 5-year
overall survival rate for patients with primary tumors was
89%, 61%, and 61%, respectively. Harrison et al. (27)
reported a 2-year survival rate of 69%, and other authors
(11, 14, 21) reported a 3- and 5-year survival rate of 55%
and 45%, respectively. In this study, patients with recurrent
tumors had a 3-year overall survival rate of 34%. Most
authors (4, 5, 7, 8, 22) reported a 3-year survival rate of
30–50%; however, other authors (10, 24) found a 3-year
survival rate of 12% and 64%. Patients with pathologic
proven positive nodes, T4 tumors, or Grade 3 differentiation
had a statistically signiﬁcant lower survival. Complete or
partial resection (4–7, 10, 11, 22, 27), the use of IORT plus
EBRT (4, 22), concomitant chemoradiotherapy (11), and
larger irradiated target areas (20) were found to be other
signiﬁcant prognostic factors by other authors.
CONCLUSION
The HDR-IORT technique for rectal cancer resulted in a
high local control rate. Because of the calculation of the
dose to the clips, we can conclude that our technique was
well carried out. The local failure rate for those with posi-
tive margins compared with those with close margins did
not differ. Because IORT out-of-ﬁeld recurrences were
common, a greater EBRT dose, a larger FIT area, or the
addition of concurrent chemotherapy may be of beneﬁt for
these patients. Patients with primary tumors had signiﬁ-
cantly greater local control and survival than did patients
with recurrent tumors. Other prognostic factors for survival
were stage and differentiation grade.
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Summary 
 
Diarrhea is the major side effect of (neo-)adjuvant radiation therapy for rectal cancer. 
Although pre-operative radiotherapy diminished the bowel toxicity, it is still a clinical 
problem. Conformal radiotherapy techniques can be used to reduce the bowel toxicity. 
Dedicated 3-D conformal radiotherapy planning for prostate cancer resulted in a low acute 
toxicity (chapter two). Sixty-four patients received definitive treatment for prostate cancer 
and were conformal treated with 72 to 80 Gy. No grade 3-4 acute, urinary or rectal 
toxicity was reported. Acute grade 2 rectal complications were seen in 10% of the patients 
treated to ≤72 Gy and in 18% of the patients treated to ≥76 Gy. Acute rectal symptoms 
were dose-volume related: patients without diarrhea had a mean rectal volume receiving a 
dose of 70 Gy or more of 8.5 cm3, however, patients with RTOG 2 diarrhea had a volume 
of 16.5 cm3 (p=0.042). Only 10% of the patients had grade 1-2 late rectal and bladder 
complications. These results demonstrate that rectal and bladder toxicity is low after 
dedicated 3-dimensional conformal treatment planning. Accurate knowledge of internal 
organ motion of the main organ at risk (small bowel) and clinical target volume (CTV) for 
rectal cancer is mandatory.  
Chapter three describes the amount and movement of small bowel inside the pelvis in pre-
operative and postoperative patients with rectal cancer. The position of any volume of 
small bowel in preoperatively treated patients was significantly more anterior (p≤0.01) 
with less volume (p≤0.04) in the pelvis than in postoperatively treated patients. This 
anatomical difference explains why the preoperatively irradiated patients in 2 randomised 
studies (Uppsala, CAO/ARO/AIO-94) had less toxicity compared to the postoperative 
patients. Blocking all or a part of the small bowel inside the radiation fields without 
knowing the CTV definition could lead to inappropriate treatment (i.e. geographical miss). 
In chapter 4, the internal motion of the CTV is calculated to create the planning target 
volume (PTV). Movement of the CTV in all dimensions was measured. The largest 
difference in the CTV occurred 10 cm cranial from the anus, (standard deviation of 1 cm). 
Bladder filling displaced the anterior border of the CTV with 7 mm on average. Other 
borders of the CTV were based on muscle, bone, or major blood vessels and were stable. 
Modification of the CTV in order to design a PTV can be unequal. This CTV was also 
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compared with the conventional 3-field technique and as a consequence of this analysis, 
we suggested to omit the block positioned on the half of the femur because it can shield a 
part of the CTV. 
The reduction of irradiated small bowel volume was investigated with intensity modulated 
conformal planning (chapter 5) compared to 3-D conformal planning. The 3-D conformal 
planning is not capable to conform the dose around the CTV with sharp gradients because 
the CTV has a large complex shape. IMRT divides each beam into numerous small 
(pencil) beams, and with these (pencil) beams intensity maps are created that result in a 
homogeneous conformal irradiated PTV and CTV with sharp gradients towards the organs 
at risk. For the conventional planning, the mean volume small bowel irradiated ≥ 95% was 
112 cm3 and for the IMRT plan 42 cm3. The amount of motion for the irradiated small 
bowel was much larger for the IMRT planning than for the conventional treatment plan. 
The use of IMRT can lead to a clinically meaningful reduction in the volume of small 
bowel irradiated. However, we are in need of clinical results that will prove this 
hypothesis (evidence based medicine). 
High-dose-rate intraoperative brachytherapy is another conformal radiotherapy technique 
and is described in chapter 6. It is a simple and adequate technique for locally advanced 
rectal tumors because small bowel and bladder can easily be pulled away from the target. 
To define the target area, clips are placed during the surgery and a 5-mm-thick flexible 
intraoperative template (FIT) with 1-cm spaced parallel catheters is used to cover the 
target area. To reduce the procedure time, treatment planning is performed using standard 
plans that neglect the curvature of the FIT. We calculated the individual treatment plan, 
based on the real geometry of the FIT, and the dose at clips placed during surgery. A 
mean treatment dose of 9.55 ± 0.21 Gy was actually found for the individual plan, instead 
of the prescribed 10 Gy (p<0.0001) at 1 cm. The largest deviation was found in the centre 
of the FIT. In 18% of the clips, the dose was smaller than 13.0 Gy indicating that locally 
the gap was larger than 5 mm. The rest of the clips received a dose higher than 13 Gy. 
These results indicate that our technique satisfies our quality assurance requirements. 
Chapter 7 reports the local failure rate, site of local recurrence and survival rate of patients 
treated with the high-dose-rate intraoperative (HDR-IORT) technique for rectal cancer. 
After exclusion of metastatic patients, 37 patients with primary locally advanced rectum 
cancer or recurrent disease were treated with external beam radiotherapy, surgery and 
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HDR-IORT. HDR-IORT was only administered if resection margins were ≤ 2 mm. A 
dose of 10 Gy was prescribed at 1 cm depth from the template surface and calculated 
using standard plans. The median follow up of surviving patients was 3 years. Overall, 12 
patients (32%) had a local recurrence, five (14%) were HDR-IORT in-field. The local 
failure rate for recurrent tumors was significantly poorer than for primary tumors. The 3-
year local failure rate was 37% for negative margins and 26% for positive margins 
(p=0.51). The overall survival was significantly different for primary/recurrent tumors, 
stage and grade. In summary, HDR-IORT can be considered as an effective treatment. 
Reasonable control rates can be obtained in the relatively poor subset of patients (with 
irradical resection margins). Also testifying to this, more out-field than in-field failures 
were seen and no difference in local failure rate in patients with positive or negative 
resection margins was found. 
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General conclusion and future perspectives 
 
Diarrhea in the treatment of locally advanced rectal cancer is still a problem. Three-
dimensional conformal treatment planning for prostate cancer enabled us to increase the 
dose without increasing the toxicity. Pre-operatively treated patients have less small bowel 
in the pelvis and have for that reason less toxicity.  With the calculated movement of the 
CTV, we are able to define a non-uniform PTV that can be irradiated using 3-D conformal 
radiotherapy techniques. However, as to be expected by the complex shape of the PTV for 
rectal cancer, the gain with 3-D conformal radiotherapy for rectal cancer is small. With 
IMRT, we are better able to shape the radiotherapy dose to the PTV and less radiation 
dose is to be received by the small bowel. Clinical results will have to prove if the toxicity 
profile of patients treated with IMRT is in fact different, i.e. lower. Intraoperative 
radiotherapy (IORT) is another technique to give a high dose to the target, while the 
organs at risk are spared to a large extent. With this technique, patients with positive 
resection margins had an equal local failure rate as the patients with close resection 
margins and also more out-field failures than in-field failures were seen. These results 
indicate that IORT is an effective therapy. Unfortunately, no randomised results are 
available. A multi-institutional randomised trial allow for a better answer to this question. 
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Samenvatting 
 
Diarree is de voornaamste complicatie van de neo-adjuvante radiotherapeutische 
behandeling van rectumkanker (hoofdstuk 1). Alhoewel pre-operative radiotherapie de 
darmtoxiciteit vermindert, is het nog steeds een klinisch probleem. Conformele 
radiotherapietechnieken kunnen gebruikt worden om de darmtoxiciteit te verminderen. 
Toegewijde drie-dimensionele conformele radiotherapieplanning voor de behandeling van 
prostaatkanker resulteerde in een lage darmtoxiciteit (hoofdstuk 2). Vierenzestig patiënten 
met prostaatkanker werden behandeld met conformele radiotherapie tot een totale dosis 
van 72 tot 80 Gy. Geen acute graad 3 of 4 blaas- of rectumtoxiciteit werd vastgesteld. 
Acute graad 2 rectumcomplicaties werden gezien in 10% van de patiënten behandeld tot 
een dosis van ≤72 Gy en in 18% van de patiënten behandeld tot ≥76 Gy. Acute 
rectumklachten waren dosis-volume gerelateerd: patiënten zonder diarree hadden een 
gemiddeld rectumvolume van 8.5 cm3 dat een dosis van 70 Gy of meer kreeg. Patiënten 
met een RTOG graad 2 diarree hadden een gemiddeld rectumvolume van 16.5 cm3 
(p=0.042). Late graad 1-2 blaas- en rectumcomplicaties werden geregistreerd in 10% van 
de patiënten. Deze resultaten tonen aan dat de blaas- en rectumtoxiciteit laag is na 
toegewijde drie-dimensionele conformele radiotherapieplanning. 
Nauwkeurige kennis van de beweging van het voornaamste risico-orgaan (dunne darm) en 
het klinische doelvolume (CTV) bij rectumkanker zijn noodzakelijk om drie-dimensionele 
conformele radiotherapieplanning voor rectumkanker toe te passen. 
Hoofdstuk 3 beschrijft het volume en de beweging van de dunne darm in het bekken bij 
pre- en postoperatieve patiënten met rectumkanker. De dunne darmen van pre-operatief 
bestraalde patiënten lagen in het bekken significant meer anterior (p≤0.01) met minder 
volume (p≤0.04) in vergelijking met postoperatief behandelde patiënten. Dit anatomische 
verschil verklaart waarom 2 gerandomiseerde studies (Upsalla, CAO/ARO/AIO-94) 
minder toxiciteit bij pre-operatief geïrradiëerde patiënten aantoonden in vergelijking met 
postoperatief geïrradiëerde patiënten. Het compleet of gedeeltelijk afschermen van de 
dunne darmen met blokken kan wel de toxiciteit verminderen, maar kan ook leiden tot een 
onefficiënte behandeling door het niet bestralen van een deel van het doelvolume, indien 
het klinische doelvolume (CTV) en zijn beweging ervan niet gekend zijn.  In hoofdstuk 4 
wordt de interne beweging van het CTV berekend om dan met die kennis een 
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planningsdoelvolume (PTV) te creëren. Beweging van het CTV werd in alle richtingen 
gemeten. De grootste beweging van het CTV kwam 10 cm craniaal van de anus voor  
(standaarddeviatie: 1 cm). Blaasvulling verschoof de anterieure grens van het CTV met 
gemiddeld 7 mm. Andere grenzen van het CTV worden bepaald door spier, bot of grote 
bloedvaten en vertonen geen beweging. Aanpassingen om van het CTV een PTV te 
maken, kunnen dus in verschillende richtingen met een ongelijke uitbreiding gebeuren. 
Het CTV werd ook vergeleken met het doelvolume van de conventionele 3-velden 
techniek. Concluderend uit dit onderzoek raden wij aan om een blok geplaatst op de helft 
van de femur weg te laten omdat dit het CTV kan afschermen. Hierdoor ontstaat er een 
onefficiënte behandeling. 
De volumereductie van bestraalde dunne darmen werd onderzocht met 
intensiteitsgemoduleerde radiotherapie (IMRT) en vergeleken met de conventionele 3-
velden techniek (hoofdstuk 5). IMRT deelt elke bestralingsbundel op in talrijke kleine 
(potlood) bundels en met deze (potlood) bundels worden intensiteitsmappen gecreëerd die 
resulteren in een homogene conformele bestraling van het CTV en PTV, met scherpe 
gradiënten naar de risico-organen. Met de conventionele planning was het volume dunne 
darm, bestraald ≥ 95%, 112 cm3 en voor de  IMRT planning 42 cm3. De beweging van het 
volume bestraalde dunne darm was veel groter voor IMRT dan voor conventionele 
planning. Het gebruik van IMRT kan leiden tot een klinisch relevante vermindering van 
het volume bestraalde dunne darm. We hebben evenwel klinische studies nodig om deze 
hypothese te bevestigen. 
Intra-operatieve HDR brachytherapie is een andere techniek in de conformele 
radiotherapie en is beschreven in hoofdstuk 6. Het is een eenvoudige en adequate techniek 
voor lokaal gevorderde rectumtumoren omdat tijdens de operatie de darmen en de blaas 
gemakkelijk van het doelvolume kunnen weggehouden worden. Om het doelvolume te 
kunnen aflijnen werden er tijdens de operatie nietjes geplaatst. Een 5-mm dik en buigzaam 
matje met parallelle holle buisjes werd op het doelvolume gelegd. In de holle buisjes 
kwam een radioactieve bron die via de computer gestuurd werd. Om de proceduretijd te 
verminderen, werd de planning gemaakt via een standaardplan dat geen rekening hield 
met de kromming van het matje. Op basis van de reële geometrie van het matje werd een 
nieuwe planning gemaakt en werd de dosis in de nietjes berekend. Een gemiddelde dosis 
van 9.55 ± 0.21 Gy werd gevonden met de nieuwe planning in plaats van de 
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voorgeschreven dosis van 10 Gy op 1cm (p<0.0001). De grootste afwijking werd 
gevonden in het centrum van het matje. In 18% van de nietjes was de dosis kleiner dan 13 
Gy, wijzend op een minder goed aangedrukt matje. De overige nietjes kregen een dosis 
hoger dan 13 Gy. Deze resultaten tonen aan dat de techniek voldoet aan onze 
kwaliteitseisen. 
Hoofdstuk 7 beschrijft het locale falen, de plaats van het locale falen en de overleving van 
patiënten met rectumkanker die behandeld zijn met intra-operatieve brachytherapie. Na 
exclusie van de gemetastaseerde patiënten, werden 37 patiënten met een primaire locaal 
gevorderde rectumtumor of met een locaal recidief behandeld met externe radiotherapie, 
chirurgie en intra-operatieve brachytherapie. Intra-operatieve brachytherapie werd alleen 
toegepast indien de resectiemarge ≤ 2 mm was. Een dosis van 10 Gy werd 
voorgeschreven op een diepte van 1 cm, berekend vanaf het oppervlak van het matje en 
gebruik makend van standaardplannen. De mediane opvolgperiode was 3 jaar. Twaalf 
patiënten (32%) ontwikkelden een locaal recidief, dat bij 5 patiënten (14%) gelegen was 
in het intra-operatieve bestralingsveld. Het locale falen kwam significant meer voor bij 
patiënten met een locaal recidief dan bij patiënten met een primaire tumor. De kans op een 
locaal recidief na 3 jaar was 37% voor patiënten met een negatief snijvlak en 26% voor 
patiënten met een positief snijvlak (p=0.51). De overleving was significant verschillend 
voor primaire/recidieverende tumoren, tumor stadium en graad. Buiten het intra-
operatieve bestralingsveld werden meer locale recidieven gevonden dan in het intra-
operatieve bestralingsveld. Ook werd geen verschil in het locale falen gevonden tussen 
patiënten met positieve en negatieve snijvlakken. Dus goede locale controle met intra-
operatieve brachytherapie kan behaald worden in een kleine groep van patiënten met 
slechte prognose. 
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Conclusie en toekomstperspectieven 
 
Diarree in de behandeling van lokaal gevorderd rectumkanker is nog steeds een probleem. 
Drie-dimensionele conformele radiotherapieplanning voor prostaatkanker stelt ons in staat 
om de radiotherapiedosis te verhogen zonder de toxiciteit te verhogen. Pre-operatief 
behandelde patiënten hebben minder dunne darmen in het bekken en daardoor minder 
toxiciteit. Met de berekende beweging van het klinisch doelvolume zijn we in staat om 
een planningsvolume te maken met ongelijke marges. Dit planningsvolume kan op zijn 
beurt gebruikt worden in de drie-dimensionele conformele radiotherapie. Door de 
ingewikkelde vorm van het planningsvolume was de winst met de drie-dimensionele 
conformele radiotherapieplanning echter gering en werd intensiteitsgemoduleerde 
radiotherapie toegepast. Met intensiteitsgemoduleerde radiotherapie zijn we beter in staat 
om de radiotherapiedosis te richten op het PTV en minder op de darmen. Klinische 
resultaten zullen in de toekomst moeten bewijzen dat de neveneffecten met een 
intensiteitsgemoduleerde radiotherapiebehandeling minder voorkomen. Intra-operatieve 
radiotherapie is een andere techniek om een hoge dosis op het doelvolume te geven 
zonder de risico-organen te bestralen. Met deze techniek hadden patiënten met een 
positief snijvlak in vergelijking met patiënten met een negatief snijvlak een gelijk aantal 
locale recidieven en werden meer locale recidieven buiten het intra-operatieve 
bestralingsveld geconstateerd dan in het bestralingsveld. Deze resultaten wijzen erop dat 
intra-operatieve radiotherapie een effectieve techniek is, alhoewel er geen 
gerandomiseerde studies bestaan. Een gerandomiseerde studie lopende in meerdere 
kankercentra zou een beter antwoord geven op deze vraag. 
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